Identification

Name
Dexamethasone
Accession Number
DB01234  (APRD00674)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]

Structure
Thumb
Synonyms
  • 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
  • 1-Dehydro-16α-methyl-9α-fluorohydrocortisone
  • 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
  • 16α-Methyl-9α-fluoro-1-dehydrocortisol
  • 9alpha-Fluoro-16alpha-methylprednisolone
  • 9α-Fluoro-16α-methylprednisolone
  • Dexametasona
  • Dexamethasone
  • Dexamethasonum
External IDs
NSC-34521
Product Ingredients
IngredientUNIICASInChI Key
Dexamethasone acetateK7V8P532WP1177-87-3AKUJBENLRBOFTD-RPRRAYFGSA-N
Dexamethasone phosphate2BP70L44PR312-93-6VQODGRNSFPNSQE-CXSFZGCWSA-N
Dexamethasone sodium phosphateAI9376Y64P2392-39-4PLCQGRYPOISRTQ-UHFFFAOYSA-L
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accufix II Dec Model 033-212Implant.7 mgIntracardiacTelectronics Pacing Systems Inc.1994-12-311999-08-27Canada
Decadron Phosphate Eye Ear Sol 0.1%Liquid1 mgAuricular (otic); OphthalmicMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1960-12-311998-04-21Canada
Decadron Phosphate Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312001-08-01Canada
Decadron Tab 0.5mgTablet.5 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1958-12-312002-07-29Canada
Decadron Tab 4mgTablet4 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-312003-08-08Canada
DexamethasoneSolution0.1 %Auricular (otic); OphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Dexamethasone Omega UnidoseSolution10 mgIntramuscular; Intrasynovial; IntravenousOmega Laboratories Ltd2013-05-08Not applicableCanada
Dexamethasone Sod Phos Inj 4mg/mlLiquid4 mgIntramuscular; IntravenousTaro Pharmaceuticals, Inc.1989-12-312001-08-21Canada
Dexamethasone Sod Phosph Inj 10mg/ml USPLiquid10 mgIntramuscular; Intrasynovial; IntravenousSandoz Canada Incorporated1990-12-31Not applicableCanada
Dexamethasone Sodium Phosphate 0.1%Solution / drops.1 %Auricular (otic); OphthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dexamethasoneTablet0.5 mgOralApotex Corporation2004-11-17Not applicableCanada
Apo-dexamethasoneTablet4 mgOralApotex Corporation2004-03-08Not applicableCanada
BaycadronElixir.5 mg/5mLOralWockhardt1983-07-27Not applicableUs
Cortaren Corticosteroid/Anti-Inflammatory SystemKitIt3 Medical Llc2017-03-01Not applicableUs
Cushings Syndrome DiagnosticKitIntegrated Pharma Solutions Llc2016-11-022017-10-31Us
DecadronTablet1.5 mg/1OralWraser Llc2017-09-112017-09-29Us
DecadronTablet4 mg/1OralPragma Pharmaceuticals, LLC2018-02-28Not applicableUs
DecadronTablet.75 mg/1OralPragma Pharmaceuticals, LLC2018-02-28Not applicableUs
DecadronTablet.5 mg/1OralPragma Pharmaceuticals, LLC2018-02-28Not applicableUs
DecadronTablet6 mg/1OralPragma Pharmaceuticals, LLC2018-02-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
999 Itch ReliefDexamethasone (15 mg/20000mg) + Camphor (200 mg/20000mg) + Menthol (200 mg/20000mg)OintmentTopicalChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.2003-07-03Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)SuspensionAuricular (otic)Physicians Total Care, Inc.2004-09-21Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)SuspensionAuricular (otic)Rebel Distributors2003-08-15Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)Suspension / dropsAuricular (otic)Alcon, Inc.2003-08-04Not applicableUs
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)SuspensionAuricular (otic)Clinical Solutions Wholsesale2003-08-152017-07-01Us
CiprodexDexamethasone (0.1 %) + Ciprofloxacin (0.3 %)SuspensionAuricular (otic)Novartis2004-05-13Not applicableCanada
CiprodexDexamethasone (1 mg/mL) + Ciprofloxacin hydrochloride (3 mg/mL)Suspension / dropsAuricular (otic)Nu Care Pharmaceuticals,inc.2003-08-04Not applicableUs
Cresophene LiqDexamethasone (1 mg) + Camphor (649 mg) + Parachlorophenol (300 mg) + Thymol (50 mg)LiquidDentalSeptodont1978-12-31Not applicableCanada
Dexlido-M KitDexamethasone sodium phosphate (10 mg/1mL) + Bupivacaine hydrochloride (2.5 mg/1mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine hydrochloride (10 mg/1mL) + Povidone-iodine (10 mg/1mL)KitProficient Rx LP2014-07-25Not applicableUs
Dioptrol OintmentDexamethasone (1 mg) + Neomycin sulfate (3.5 mg) + Polymyxin B Sulfate (10000 unit)OintmentOphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dex-MoxiDexamethasone sodium phosphate (1 mg/mL) + Moxifloxacin hydrochloride monohydrate (5 mg/mL)Injection, solutionOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Dex-Moxi PFDexamethasone sodium phosphate (1 mg/mL) + Moxifloxacin hydrochloride monohydrate (5 mg/mL)Injection, solutionIntraocularImprimis Rx Nj2018-01-01Not applicableUs
Dex-Moxi-KetorDexamethasone sodium phosphate (1 mg/mL) + Ketorolac tromethamine (.4 mg/mL) + Moxifloxacin hydrochloride monohydrate (.5 mg/mL)Injection, solutionOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
DexMoxiKetor PFDexamethasone sodium phosphate (1 mg/mL) + Ketorolac tromethamine (.4 mg/mL) + Moxifloxacin hydrochloride monohydrate (.5 mg/mL)Injection, solutionIntraocularImprimis Rx Nj2018-01-01Not applicableUs
Dmt SuikDexamethasone sodium phosphate (10 mg/mL)Injection, solutionIntramuscular; IntravenousAsclemed Usa, Inc.2003-05-29Not applicableUs
Gati-DexDexamethasone sodium phosphate (1 mg/mL) + Gatifloxacin (5 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
International/Other Brands
Decadron (Sidus)
Categories
UNII
7S5I7G3JQL
CAS number
50-02-2
Weight
Average: 392.4611
Monoisotopic: 392.199902243
Chemical Formula
C22H29FO5
InChI Key
UREBDLICKHMUKA-CXSFZGCWSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

Injection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps

Associated Conditions
Pharmacodynamics

Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.

Mechanism of action

Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UNuclear receptor subfamily 0 group B member 1
stimulator
Human
UAnnexin A1
agonist
Human
UNitric oxide synthase, inducible
negative modulator
Human
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
Absorption

80-90%

Volume of distribution
Not Available
Protein binding

70%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

36-54 hours

Clearance
Not Available
Toxicity

Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe serum concentration of (R)-warfarin can be decreased when it is combined with Dexamethasone.Experimental
(S)-WarfarinThe serum concentration of (S)-Warfarin can be decreased when it is combined with Dexamethasone.Experimental, Investigational
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Dexamethasone.Experimental, Illicit, Investigational
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dexamethasone.Experimental
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Dexamethasone.Investigational
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Dexamethasone.Experimental, Illicit
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Dexamethasone.Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 2-Methoxyethanol.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Dexamethasone.Investigational
3,5-diiodothyropropionic acidThe serum concentration of 3,5-diiodothyropropionic acid can be decreased when it is combined with Dexamethasone.Investigational
4-hydroxycoumarinThe serum concentration of 4-hydroxycoumarin can be decreased when it is combined with Dexamethasone.Experimental
4-HydroxytestosteroneThe risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Dexamethasone.Experimental, Illicit
5-androstenedioneThe risk or severity of edema formation can be increased when 5-androstenedione is combined with Dexamethasone.Experimental, Illicit
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be decreased when it is combined with Dexamethasone.Investigational
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Dexamethasone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Dexamethasone.Approved
AbediterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Abediterol.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Dexamethasone.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Abetimus.Investigational
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Dexamethasone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Dexamethasone.Approved, Investigational
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Dexamethasone.Approved, Investigational
AcetaminophenThe serum concentration of Dexamethasone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexamethasone.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Dexamethasone.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Dexamethasone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Dexamethasone.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Afelimomab.Investigational
AgmatineThe serum concentration of Agmatine can be decreased when it is combined with Dexamethasone.Experimental, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dexamethasone.Experimental, Investigational
AlbendazoleThe serum concentration of Dexamethasone can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Dexamethasone.Approved
AlclofenacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Alclometasone.Approved
AlcuroniumThe risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Dexamethasone.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Dexamethasone can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone.Approved, Investigational
AlfacalcidolThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Dexamethasone.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Dexamethasone.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Dexamethasone.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Dexamethasone.Approved
AlmasilateThe bioavailability of Dexamethasone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Alminoprofen.Experimental
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Dexamethasone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dexamethasone.Approved
AloglutamolThe bioavailability of Dexamethasone can be decreased when combined with Aloglutamol.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Dexamethasone.Experimental
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Dexamethasone.Approved
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Dexamethasone.Approved
AluminiumThe bioavailability of Dexamethasone can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Dexamethasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Aluminium clofibrate.Experimental
Aluminium glycinateThe bioavailability of Dexamethasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminium phosphateThe bioavailability of Dexamethasone can be decreased when combined with Aluminium phosphate.Approved, Investigational
Aluminum hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AlvocidibThe serum concentration of Alvocidib can be increased when it is combined with Dexamethasone.Experimental, Investigational
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Dexamethasone.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Dexamethasone.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Dexamethasone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Amcinonide.Approved
AMG-222The therapeutic efficacy of AMG-222 can be decreased when used in combination with Dexamethasone.Investigational
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dexamethasone.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexamethasone.Approved
AmiodaroneThe serum concentration of Dexamethasone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Dexamethasone.Approved
AmlodipineThe serum concentration of Dexamethasone can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Dexamethasone can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Dexamethasone can be increased when it is combined with Amoxapine.Approved
Amphotericin BThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Dexamethasone.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Dexamethasone.Approved, Investigational
AnagliptinThe therapeutic efficacy of Anagliptin can be decreased when used in combination with Dexamethasone.Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Dexamethasone.Approved
AndrostenediolThe risk or severity of edema formation can be increased when Androstenediol is combined with Dexamethasone.Experimental, Illicit
AndrostenedioneThe risk or severity of edema formation can be increased when Androstenedione is combined with Dexamethasone.Experimental, Illicit
AnnamycinThe serum concentration of Dexamethasone can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dexamethasone.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Dexamethasone.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Dexamethasone.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Dexamethasone.Approved, Investigational
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Dexamethasone.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone.Approved
AntrafenineThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Dexamethasone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Dexamethasone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe serum concentration of Aranidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
ArbutamineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Arbutamine.Approved
ArformoterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Dexamethasone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
Aripiprazole lauroxilThe serum concentration of Aripiprazole lauroxil can be decreased when it is combined with Dexamethasone.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Dexamethasone.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Dexamethasone.Approved
Asparaginase Erwinia chrysanthemiThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.Approved, Investigational
Asparaginase Escherichia coliThe serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Escherichia coli.Approved, Investigational
AstemizoleThe serum concentration of Dexamethasone can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of edema formation can be increased when Atamestane is combined with Dexamethasone.Investigational
AtazanavirThe metabolism of Dexamethasone can be decreased when combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Dexamethasone can be increased when it is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Dexamethasone.Approved
AtracuriumThe risk or severity of myopathy and weakness can be increased when Atracurium is combined with Dexamethasone.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Dexamethasone.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Dexamethasone.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Dexamethasone.Approved, Investigational
AzapropazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Dexamethasone.Approved
AzelastineThe serum concentration of Dexamethasone can be increased when it is combined with Azelastine.Approved
AzelnidipineThe serum concentration of Azelnidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
AzithromycinThe serum concentration of Dexamethasone can be increased when it is combined with Azithromycin.Approved
AzosemideThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dexamethasone.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dexamethasone.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Dexamethasone.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Dexamethasone.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Dexamethasone.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Dexamethasone.Approved
Bafilomycin A1The serum concentration of Dexamethasone can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Dexamethasone can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Dexamethasone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone.Approved, Investigational
BambuterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Bambuterol.Approved, Investigational
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Dexamethasone.Investigational
BaricitinibThe serum concentration of Baricitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be decreased when it is combined with Dexamethasone.Approved
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Dexamethasone.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dexamethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Beclomethasone dipropionate.Approved, Investigational
BecocalcidiolThe therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Dexamethasone.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Dexamethasone.Approved
BegelomabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Begelomab.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Dexamethasone.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Dexamethasone.Approved
BelinostatThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Belinostat.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Dexamethasone.Investigational
BencyclaneThe serum concentration of Bencyclane can be decreased when it is combined with Dexamethasone.Experimental
BendamustineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Bendamustine.Approved, Investigational
BendazacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bendazac.Experimental
BendroflumethiazideDexamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenfluorexThe therapeutic efficacy of Benfluorex can be decreased when used in combination with Dexamethasone.Investigational, Withdrawn
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
BenorilateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Dexamethasone.Approved, Investigational
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Dexamethasone.Approved, Illicit
BenzquinamideThe serum concentration of Dexamethasone can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazideDexamethasone may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Benzydamine.Approved
Benzyl alcoholThe serum concentration of Dexamethasone can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Besifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dexamethasone.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Bevacizumab.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Bexarotene.Approved, Investigational
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Bezafibrate.Approved, Investigational
BicalutamideThe serum concentration of Dexamethasone can be increased when it is combined with Bicalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Dexamethasone.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be decreased when it is combined with Dexamethasone.Approved, Experimental
Biricodar dicitrateThe serum concentration of Dexamethasone can be increased when it is combined with Biricodar dicitrate.Investigational
Bismuth subnitrateThe bioavailability of Dexamethasone can be decreased when combined with Bismuth subnitrate.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Dexamethasone.Approved
BitolterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Bitolterol.Withdrawn
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Dexamethasone.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Blinatumomab.Approved, Investigational
BlonanserinThe serum concentration of Blonanserin can be decreased when it is combined with Dexamethasone.Approved, Investigational
BoceprevirThe metabolism of Dexamethasone can be decreased when combined with Boceprevir.Approved, Withdrawn
BolandiolThe risk or severity of edema formation can be increased when Bolandiol is combined with Dexamethasone.Experimental, Illicit
BolasteroneThe risk or severity of edema formation can be increased when Bolasterone is combined with Dexamethasone.Experimental, Illicit
BoldenoneThe risk or severity of edema formation can be increased when Boldenone is combined with Dexamethasone.Illicit, Vet Approved
BortezomibThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dexamethasone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dexamethasone.Approved
Brefeldin AThe serum concentration of Dexamethasone can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Briakinumab.Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Dexamethasone.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Dexamethasone.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Dexamethasone.Approved, Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Brodalumab.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
BromfenacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bromfenac.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Dexamethasone.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Dexamethasone.Approved
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Dexamethasone.Approved
BufexamacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Dexamethasone.Investigational, Withdrawn
BumadizoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bumadizone.Experimental
BumetanideThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Dexamethasone.Approved, Investigational
BuprenorphineThe serum concentration of Dexamethasone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Dexamethasone.Approved
BuspironeThe serum concentration of Dexamethasone can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Dexamethasone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cabazitaxel.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Dexamethasone.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
CaffeineThe serum concentration of Dexamethasone can be increased when it is combined with Caffeine.Approved
CalcidiolThe therapeutic efficacy of Calcidiol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
CalcipotriolThe therapeutic efficacy of Calcipotriol can be decreased when used in combination with Dexamethasone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Dexamethasone can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Dexamethasone can be decreased when combined with Calcium silicate.Experimental
CalusteroneThe risk or severity of edema formation can be increased when Calusterone is combined with Dexamethasone.Experimental, Illicit
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dexamethasone.Experimental
CanagliflozinThe serum concentration of Dexamethasone can be increased when it is combined with Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Dexamethasone.Approved, Investigational
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Dexamethasone.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Dexamethasone.Approved, Investigational
Capromab pendetideDexamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Dexamethasone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Dexamethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexamethasone.Experimental, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Dexamethasone.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Dexamethasone.Approved
CarboxyamidotriazoleThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Dexamethasone.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Dexamethasone.Experimental
CarfilzomibThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Carfilzomib.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Dexamethasone.Approved, Investigational
CarmegliptinThe therapeutic efficacy of Carmegliptin can be decreased when used in combination with Dexamethasone.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Dexamethasone.Approved, Investigational
CaroverineThe serum concentration of Caroverine can be decreased when it is combined with Dexamethasone.Experimental
CarprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Dexamethasone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Castanospermine.Experimental
CefoperazoneThe serum concentration of Dexamethasone can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Dexamethasone can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational
CeliprololThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Celiprolol.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Dexamethasone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dexamethasone.Approved, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Dexamethasone.Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Dexamethasone.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dexamethasone.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexamethasone.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
ChlormadinoneThe serum concentration of Dexamethasone can be increased when it is combined with Chlormadinone.Experimental
ChloroformThe serum concentration of Dexamethasone can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
ChlorothiazideDexamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Dexamethasone.Approved
ChlorpromazineThe serum concentration of Dexamethasone can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone.Approved, Investigational
ChlorprothixeneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneDexamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dexamethasone.Approved
CholecalciferolThe therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ciclesonide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dexamethasone.Experimental
CilnidipineThe serum concentration of Cilnidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Dexamethasone.Approved, Investigational
CimicoxibThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Cimicoxib.Investigational
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Dexamethasone.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Dexamethasone.Approved, Investigational
CinoxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Dexamethasone.Approved
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Dexamethasone.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Dexamethasone.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Dexamethasone.Approved, Investigational
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Dexamethasone.Approved
ClenbuterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Dexamethasone.Approved, Investigational
ClofazimineThe serum concentration of Dexamethasone can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Clofibride.Experimental
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Dexamethasone.Investigational
ClomipramineThe serum concentration of Dexamethasone can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Dexamethasone.Approved
ClonixinThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Dexamethasone.Approved
CloprednolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cloprednol.Experimental
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClorindioneThe serum concentration of Clorindione can be decreased when it is combined with Dexamethasone.Experimental
ClostebolThe risk or severity of edema formation can be increased when Clostebol is combined with Dexamethasone.Experimental, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.Approved
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
ClotrimazoleThe metabolism of Dexamethasone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Dexamethasone.Approved
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Dexamethasone.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Dexamethasone.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Dexamethasone.Approved, Illicit
ColchicineThe serum concentration of Dexamethasone can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Dexamethasone can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Dexamethasone.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Dexamethasone.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Dexamethasone.Approved, Investigational
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone.Approved
CorticosteroneThe serum concentration of Corticosterone can be decreased when it is combined with Dexamethasone.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.Approved
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Dexamethasone.Vet Approved
CrizotinibThe serum concentration of Dexamethasone can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Dexamethasone can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe serum concentration of Cyclandelate can be decreased when it is combined with Dexamethasone.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dexamethasone.Approved
CyclopenthiazideDexamethasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dexamethasone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Dexamethasone.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Dexamethasone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.Approved
DabrafenibThe serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Dexamethasone.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Dexamethasone.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Dexamethasone.Approved, Investigational
DanazolThe risk or severity of fluid retention can be increased when Dexamethasone is combined with Danazol.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Dexamethasone.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dexamethasone.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Dexamethasone.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be decreased when it is combined with Dexamethasone.Experimental
DarunavirThe metabolism of Dexamethasone can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Dexamethasone.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Dexamethasone.Approved
DecamethoniumThe risk or severity of myopathy and weakness can be increased when Decamethonium is combined with Dexamethasone.Approved
DecitabineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Deflazacort.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be increased when it is combined with Dexamethasone.Approved, Investigational
DelamanidThe serum concentration of Delamanid can be decreased when it is combined with Dexamethasone.Approved, Investigational
DelavirdineThe metabolism of Dexamethasone can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Dexamethasone.Approved
DemegestoneThe serum concentration of Demegestone can be decreased when it is combined with Dexamethasone.Approved
DenosumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Deoxyspergualin.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Dexamethasone.Investigational
DesipramineThe serum concentration of Dexamethasone can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Dexamethasone can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe serum concentration of Dexamethasone can be increased when it is combined with Desogestrel.Approved
DesonideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Dexamethasone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Dexamethasone.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Dexamethasone.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Dexamethasone.Approved, Investigational
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dexamethasone isonicotinate.Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Dexamethasone.Approved
DexibuprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Dexketoprofen.Approved, Investigational
DexlansoprazoleThe serum concentration of Dexlansoprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
DexniguldipineThe serum concentration of Dexamethasone can be increased when it is combined with Dexniguldipine.Experimental
DexrabeprazoleThe serum concentration of Dexrabeprazole can be decreased when it is combined with Dexamethasone.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Dexamethasone.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Dexamethasone can be increased when it is combined with Dexverapamil.Experimental
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Vet Approved
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Dexamethasone.Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Dexamethasone.Approved
DienogestThe risk or severity of edema formation can be increased when Dienogest is combined with Dexamethasone.Approved
Diethyl etherThe serum concentration of Dexamethasone can be increased when it is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dexamethasone.Approved, Investigational
DifenpiramideThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Diflorasone.Approved
DifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Dexamethasone.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Dexamethasone.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Dexamethasone.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dexamethasone.Approved, Illicit
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Dexamethasone.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Dexamethasone.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Dexamethasone.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Dexamethasone.Approved, Investigational
DihydrotachysterolThe therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Dexamethasone.Approved
DiltiazemThe metabolism of Dexamethasone can be decreased when combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dimethyl fumarate.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Dinutuximab.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be decreased when it is combined with Dexamethasone.Experimental
DipivefrinThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Dipivefrin.Approved
DipyridamoleThe serum concentration of Dexamethasone can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Dexamethasone.Approved
DistigmineThe therapeutic efficacy of Distigmine can be decreased when used in combination with Dexamethasone.Experimental
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Dexamethasone.Approved
DobutamineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Docetaxel.Approved, Investigational
DofequidarThe serum concentration of Dexamethasone can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Dexamethasone.Approved, Investigational
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Dexamethasone.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Dexamethasone.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Dexamethasone.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Dexamethasone.Approved
DotarizineThe serum concentration of Dotarizine can be decreased when it is combined with Dexamethasone.Investigational
DovitinibThe serum concentration of Dexamethasone can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Dexamethasone.Approved
DoxazosinThe serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Dexamethasone can be increased when it is combined with Doxepin.Approved, Investigational
DoxercalciferolThe therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Dexamethasone.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Doxifluridine.Investigational
DoxofyllineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Dexamethasone.Approved, Investigational
DoxycyclineThe metabolism of Dexamethasone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dexamethasone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Dexamethasone can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Dexamethasone can be increased when it is combined with Drospirenone.Approved
DroxicamThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Droxicam.Withdrawn
DroxidopaThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dexamethasone.Approved, Investigational
DuloxetineThe serum concentration of Dexamethasone can be increased when it is combined with Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Dexamethasone.Approved, Investigational
DutogliptinThe therapeutic efficacy of Dutogliptin can be decreased when used in combination with Dexamethasone.Investigational
DydrogesteroneThe serum concentration of Dydrogesterone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Dexamethasone.Approved
EconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Econazole.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Dexamethasone.Approved, Investigational
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Dexamethasone.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Efalizumab.Approved, Investigational
EfavirenzThe metabolism of Dexamethasone can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe serum concentration of Efonidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
ElacridarThe serum concentration of Dexamethasone can be increased when it is combined with Elacridar.Investigational
ElbasvirThe serum concentration of Elbasvir can be decreased when it is combined with Dexamethasone.Approved
EldecalcitolThe therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Dexamethasone.Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Dexamethasone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Dexamethasone.Approved
ElocalcitolThe therapeutic efficacy of Elocalcitol can be decreased when used in combination with Dexamethasone.Investigational
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Dexamethasone.Approved
EmopamilThe serum concentration of Dexamethasone can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Dexamethasone.Approved, Investigational
EncorafenibThe serum concentration of Encorafenib can be decreased when it is combined with Dexamethasone.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Dexamethasone.Experimental
EnoxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Dexamethasone.Approved
EperisoneThe serum concentration of Eperisone can be decreased when it is combined with Dexamethasone.Approved, Investigational
EphedraThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Dexamethasone.Approved, Investigational
EpinephrineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Dexamethasone.Approved
EpitizideDexamethasone may increase the hypokalemic activities of Epitizide.Experimental
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Dexamethasone.Approved
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Dexamethasone.Experimental
EquilinThe serum concentration of Equilin can be decreased when it is combined with Dexamethasone.Approved
ErgocalciferolThe therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Dexamethasone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Dexamethasone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Dexamethasone.Approved
EribulinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Dexamethasone can be increased when it is combined with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Dexamethasone.Approved, Investigational
ErythromycinThe serum concentration of Dexamethasone can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Dexamethasone.Approved, Investigational
EsomeprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Dexamethasone.Approved, Illicit
EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Dexamethasone.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Dexamethasone.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Dexamethasone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dexamethasone.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Dexamethasone.Approved, Investigational
Etacrynic acidThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Etafedrine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Dexamethasone.Approved
EthenzamideThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Dexamethasone.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Dexamethasone.Withdrawn
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Dexamethasone.Approved, Illicit
EthynodiolThe serum concentration of Dexamethasone can be increased when it is combined with Ethynodiol.Experimental
Ethynodiol diacetateThe serum concentration of Dexamethasone can be increased when it is combined with Ethynodiol diacetate.Approved
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Dexamethasone.Approved
EtodolacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Etofenamate.Approved, Investigational
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Etofibrate.Approved
EtonogestrelThe serum concentration of Dexamethasone can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Dexamethasone.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Dexamethasone.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Dexamethasone.Approved
EvogliptinThe therapeutic efficacy of Evogliptin can be decreased when used in combination with Dexamethasone.Investigational
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Dexamethasone.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Dexamethasone.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Dexamethasone.Approved, Investigational
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Dexamethasone.Approved
FelbinacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Felbinac.Experimental
FelodipineThe serum concentration of Dexamethasone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Fenbufen.Approved
FendilineThe serum concentration of Fendiline can be decreased when it is combined with Dexamethasone.Withdrawn
FenofibrateThe serum concentration of Dexamethasone can be increased when it is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Fenofibric acid.Approved
FenoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Fenoprofen.Approved
FenoterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Fenoterol.Approved, Investigational
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Dexamethasone.Vet Approved
FentiazacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Feprazone.Experimental
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Dexamethasone.Approved
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Dexamethasone.Approved, Investigational
FirocoxibThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Firocoxib.Experimental, Vet Approved
Fish oilThe serum concentration of Fish oil can be decreased when it is combined with Dexamethasone.Approved, Nutraceutical
FleroxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Fleroxacin.Approved
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Dexamethasone.Approved, Investigational
FloctafenineThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Dexamethasone.Approved
FluasteroneThe risk or severity of edema formation can be increased when Fluasterone is combined with Dexamethasone.Investigational
FlucloroloneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluclorolone.Experimental
FluconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Dexamethasone.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dexamethasone.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be decreased when it is combined with Dexamethasone.Approved, Investigational
FlumequineThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Dexamethasone.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flunisolide.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
FlunixinThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Dexamethasone.Approved
FluoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneThe risk or severity of fluid retention can be increased when Dexamethasone is combined with Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Dexamethasone can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluperolone.Experimental
FluphenazineThe serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Dexamethasone can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Flurbiprofen.Approved, Investigational
FluspirileneThe serum concentration of Fluspirilene can be decreased when it is combined with Dexamethasone.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Dexamethasone.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluticasone propionate.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Dexamethasone is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Dexamethasone can be increased when it is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe serum concentration of Folic Acid can be increased when it is combined with Dexamethasone.Approved, Nutraceutical, Vet Approved
FormestaneThe risk or severity of edema formation can be increased when Formestane is combined with Dexamethasone.Approved, Investigational, Withdrawn
FormocortalThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Formocortal.Experimental
FormoterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Dexamethasone.Approved
FosaprepitantThe serum concentration of Dexamethasone can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be decreased when it is combined with Dexamethasone.Approved
FosphenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of Fostamatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Dexamethasone.Approved, Investigational
FurosemideThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dexamethasone can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Dexamethasone.Investigational
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Dexamethasone.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Dexamethasone.Approved
GallamineThe risk or severity of myopathy and weakness can be increased when Gallamine is combined with Dexamethasone.Experimental
Gallamine TriethiodideThe risk or severity of myopathy and weakness can be increased when Gallamine Triethiodide is combined with Dexamethasone.Approved
Gallium nitrateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Gallium nitrate.Approved, Investigational
GallopamilThe serum concentration of Dexamethasone can be increased when it is combined with Gallopamil.Investigational
GarenoxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dexamethasone.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Dexamethasone.Approved
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Gemifloxacin.Approved, Investigational
GemigliptinThe therapeutic efficacy of Gemigliptin can be decreased when used in combination with Dexamethasone.Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone.Approved, Investigational
GenisteinThe serum concentration of Dexamethasone can be increased when it is combined with Genistein.Investigational
GestodeneThe serum concentration of Dexamethasone can be increased when it is combined with Gestodene.Approved, Investigational
GestrinoneThe serum concentration of Gestrinone can be decreased when it is combined with Dexamethasone.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Dexamethasone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Dexamethasone.Approved, Investigational, Nutraceutical
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Dexamethasone.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Dexamethasone.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Dexamethasone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Dexamethasone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dexamethasone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be decreased when used in combination with Dexamethasone.Investigational
GLPG-0492The risk or severity of fluid retention can be increased when Dexamethasone is combined with GLPG-0492.Investigational
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Dexamethasone.Approved
GlycerinThe serum concentration of Dexamethasone can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Dexamethasone.Approved
GlycodiazineThe therapeutic efficacy of Glycodiazine can be decreased when used in combination with Dexamethasone.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Dexamethasone.Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be decreased when used in combination with Dexamethasone.Investigational
Gramicidin DThe serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Dexamethasone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Dexamethasone.Approved
GrepafloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Dexamethasone.Experimental
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Dexamethasone.Approved, Investigational
Guar gumThe therapeutic efficacy of Guar gum can be decreased when used in combination with Dexamethasone.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Dexamethasone.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Halcinonide.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Dexamethasone.Approved
HalometasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Halometasone.Experimental
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Dexamethasone.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be decreased when it is combined with Dexamethasone.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dexamethasone.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dexamethasone.Approved, Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Dexamethasone.Approved
HexoprenalineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Hexoprenaline.Approved, Withdrawn
HistamineThe serum concentration of Histamine can be decreased when it is combined with Dexamethasone.Approved, Investigational
HM-30181The serum concentration of Dexamethasone can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Dexamethasone.Approved
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Dexamethasone.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.Approved, Investigational
HycanthoneThe serum concentration of Dexamethasone can be increased when it is combined with Hycanthone.Approved, Investigational
HydrochlorothiazideDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Dexamethasone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Dexamethasone.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone cypionateThe serum concentration of Hydrocortisone cypionate can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
Hydrocortisone phosphateThe serum concentration of Hydrocortisone phosphate can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideDexamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Dexamethasone.Approved, Illicit
HydrotalciteThe bioavailability of Dexamethasone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxychloroquineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hydroxychloroquine.Approved
HydroxyprogesteroneThe serum concentration of Hydroxyprogesterone can be decreased when it is combined with Dexamethasone.Experimental
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dexamethasone.Approved, Investigational
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Dexamethasone.Approved
HypericinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hypericin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Dexamethasone.Approved
IbuprofenThe serum concentration of Dexamethasone can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Icosapent.Approved, Nutraceutical
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Dexamethasone.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dexamethasone resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Dexamethasone.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Dexamethasone.Approved, Investigational
Imidazole salicylateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Dexamethasone.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Dexamethasone.Approved, Investigational
IndacaterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Indacaterol.Approved
IndapamideDexamethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Dexamethasone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Indobufen.Investigational
IndomethacinThe serum concentration of Dexamethasone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Indoprofen.Withdrawn
InecalcitolThe therapeutic efficacy of Inecalcitol can be decreased when used in combination with Dexamethasone.Experimental, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Dexamethasone.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Dexamethasone.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Dexamethasone.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be decreased when used in combination with Dexamethasone.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Dexamethasone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Dexamethasone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Dexamethasone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Dexamethasone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Dexamethasone.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dexamethasone.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Dexamethasone is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Dexamethasone is combined with Interferon alfacon-1.Approved, Investigational
IpecacThe serum concentration of Ipecac can be decreased when it is combined with Dexamethasone.Approved, Withdrawn
IpidacrineThe therapeutic efficacy of Ipidacrine can be decreased when used in combination with Dexamethasone.Experimental
IpratropiumThe serum concentration of Ipratropium can be decreased when it is combined with Dexamethasone.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Dexamethasone.Approved, Investigational
IsavuconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Dexamethasone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Isoetarine.Approved
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dexamethasone.Approved, Investigational, Withdrawn
IsoniazidThe therapeutic efficacy of Isoniazid can be decreased when used in combination with Dexamethasone.Approved, Investigational
IsoprenalineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Dexamethasone.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dexamethasone.Approved
IsoxicamThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Isoxicam.Withdrawn
IsradipineThe serum concentration of Dexamethasone can be increased when it is combined with Isradipine.Approved, Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Dexamethasone.Investigational
ItraconazoleThe metabolism of Dexamethasone can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Dexamethasone.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Dexamethasone can be increased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Dexamethasone.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Dexamethasone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.Approved
KebuzoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Kebuzone.Experimental
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Dexamethasone.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Dexamethasone.Approved, Investigational
KetoconazoleThe metabolism of Dexamethasone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ketorolac.Approved
KRP-104The therapeutic efficacy of KRP-104 can be decreased when used in combination with Dexamethasone.Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Dexamethasone.Approved, Investigational, Nutraceutical
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dexamethasone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LaniquidarThe serum concentration of Dexamethasone can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Dexamethasone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Dexamethasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Dexamethasone.Approved, Investigational
LenalidomideDexamethasone may increase the thrombogenic activities of Lenalidomide.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dexamethasone.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LetermovirThe serum concentration of Dexamethasone can be increased when it is combined with Letermovir.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Dexamethasone.Approved, Investigational
LeuprolideThe serum concentration of Leuprolide can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Dexamethasone.Approved
LevofloxacinThe serum concentration of Dexamethasone can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Dexamethasone.Approved, Investigational
LevonorgestrelThe serum concentration of Dexamethasone can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevosalbutamolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Levosalbutamol.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Dexamethasone.Approved
LidocaineThe serum concentration of Dexamethasone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe serum concentration of Lidoflazine can be decreased when it is combined with Dexamethasone.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Linezolid.Approved, Investigational
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Dexamethasone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Dexamethasone.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Dexamethasone.Approved, Investigational
LixisenatideThe therapeutic efficacy of Lixisenatide can be decreased when used in combination with Dexamethasone.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational
LomefloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Lomefloxacin.Approved, Investigational
LomerizineThe serum concentration of Dexamethasone can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Dexamethasone can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Dexamethasone.Approved, Investigational
LonafarnibThe serum concentration of Dexamethasone can be increased when it is combined with Lonafarnib.Investigational
LonazolacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Dexamethasone can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Dexamethasone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Dexamethasone can be increased when it is combined with Loratadine.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Dexamethasone.Approved
LornoxicamThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Dexamethasone can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Loteprednol.Approved
LovastatinThe serum concentration of Dexamethasone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Dexamethasone can be increased when it is combined with Loxapine.Approved
LoxoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dexamethasone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Dexamethasone.Approved
LumiracoxibThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Lumiracoxib.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Dexamethasone.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Dexamethasone.Approved, Investigational
LynestrenolThe serum concentration of Dexamethasone can be increased when it is combined with Lynestrenol.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Dexamethasone.Illicit, Investigational, Withdrawn
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Dexamethasone.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Dexamethasone.Approved
MagaldrateThe bioavailability of Dexamethasone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Dexamethasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Magnesium salicylate.Approved
Magnesium silicateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium silicate.Approved
Magnesium sulfateThe serum concentration of Magnesium sulfate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Dexamethasone.Approved, Investigational
ManidipineThe serum concentration of Manidipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Dexamethasone.Approved, Investigational
MaxacalcitolThe therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Dexamethasone.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
MecaserminThe therapeutic efficacy of Mecasermin can be decreased when used in combination with Dexamethasone.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dexamethasone.Approved, Investigational
Meclofenamic acidThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Meclofenamic acid.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be decreased when it is combined with Dexamethasone.Experimental, Investigational
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Dexamethasone.Approved
Medroxyprogesterone acetateThe serum concentration of Dexamethasone can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Dexamethasone can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Dexamethasone can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Melengestrol.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Dexamethasone.Approved
MentholThe serum concentration of Menthol can be decreased when it is combined with Dexamethasone.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Dexamethasone.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Dexamethasone.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone.Approved
MesteroloneThe risk or severity of edema formation can be increased when Mesterolone is combined with Dexamethasone.Experimental
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Dexamethasone.Approved
MetahexamideThe therapeutic efficacy of Metahexamide can be decreased when used in combination with Dexamethasone.Experimental
MetamizoleThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Metamizole.Approved, Investigational, Withdrawn
MetenoloneThe risk or severity of edema formation can be increased when Metenolone is combined with Dexamethasone.Experimental
MetergolineThe metabolism of Metergoline can be decreased when combined with Dexamethasone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.Approved
MethadoneThe serum concentration of Dexamethasone can be increased when it is combined with Methadone.Approved
Methanesulfonyl FluorideThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Dexamethasone.Investigational
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Dexamethasone.Illicit, Withdrawn
MethimazoleThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Dexamethasone.Approved
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Dexamethasone.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
MethyclothiazideDexamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone.Approved, Vet Approved
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Dexamethasone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dexamethasone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of edema formation can be increased when Methyltestosterone is combined with Dexamethasone.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Dexamethasone.Approved
MetoclopramideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dexamethasone.Approved, Investigational
MetocurineThe risk or severity of myopathy and weakness can be increased when Metocurine is combined with Dexamethasone.Approved
Metocurine IodideThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Dexamethasone.Approved, Withdrawn
MetolazoneDexamethasone may increase the hypokalemic activities of Metolazone.Approved
MetronidazoleThe serum concentration of Dexamethasone can be increased when it is combined with Metronidazole.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Dexamethasone is combined with Mevastatin.Experimental
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Dexamethasone.Approved, Investigational
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Dexamethasone.Approved, Investigational
MibefradilThe metabolism of Dexamethasone can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiboleroneThe risk or severity of edema formation can be increased when Mibolerone is combined with Dexamethasone.Vet Approved
MiconazoleThe serum concentration of Dexamethasone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Dexamethasone can be increased when it is combined with Midazolam.Approved, Illicit
MidecamycinThe serum concentration of Midecamycin can be decreased when it is combined with Dexamethasone.Approved
MidostaurinThe serum concentration of Midostaurin can be decreased when it is combined with Dexamethasone.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Dexamethasone.Approved, Experimental
MifepristoneThe serum concentration of Dexamethasone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone.Approved
MinaprineThe therapeutic efficacy of Minaprine can be decreased when used in combination with Dexamethasone.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Dexamethasone.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Dexamethasone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Dexamethasone.Approved
MitotaneThe serum concentration of Dexamethasone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dexamethasone.Approved, Investigational
MivacuriumThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Dexamethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Dexamethasone can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Dexamethasone can be increased when it is combined with Monensin.Vet Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Dexamethasone.Approved
MorniflumateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Dexamethasone.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
MoxifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Moxifloxacin.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dexamethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.Approved
NabiximolsThe serum concentration of Nabiximols can be decreased when it is combined with Dexamethasone.Approved, Investigational
NabumetoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Nabumetone.Approved
NafcillinThe serum concentration of Dexamethasone can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftopidilThe serum concentration of Naftopidil can be decreased when it is combined with Dexamethasone.Investigational
Nalidixic AcidThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Dexamethasone.Approved
NaloxoneThe metabolism of Dexamethasone can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe serum concentration of Naltrexone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
NandroloneThe risk or severity of edema formation can be increased when Nandrolone is combined with Dexamethasone.Experimental, Investigational
Nandrolone decanoateThe risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Dexamethasone.Approved, Illicit
Nandrolone phenpropionateThe risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Dexamethasone.Approved, Illicit, Investigational
NaproxenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Dexamethasone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Dexamethasone.Investigational
NefazodoneThe metabolism of Dexamethasone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Dexamethasone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Nemonoxacin.Investigational
NeosaxitoxinThe risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Dexamethasone.Investigational
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Dexamethasone.Approved, Vet Approved
NepafenacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Nepafenac.Approved, Investigational
NeratinibThe serum concentration of Dexamethasone can be increased when it is combined with Neratinib.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be decreased when used in combination with Dexamethasone.Experimental
NetupitantThe serum concentration of Dexamethasone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Dexamethasone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Dexamethasone can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Dexamethasone.Approved, Investigational
NicorandilThe risk or severity of ulceration can be increased when Dexamethasone is combined with Nicorandil.Approved, Investigational
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Dexamethasone.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Dexamethasone.Approved
NifenazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Niflumic Acid.Approved
NigericinThe serum concentration of Dexamethasone can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Dexamethasone can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be decreased when it is combined with Dexamethasone.Experimental
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
NimesulideThe serum concentration of Nimesulide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Dexamethasone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Dexamethasone.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Dexamethasone.Approved
NitrendipineThe serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexamethasone.Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be increased when it is combined with Dexamethasone.Approved, Vet Approved
NN344The therapeutic efficacy of NN344 can be decreased when used in combination with Dexamethasone.Investigational
NomegestrolThe serum concentration of Dexamethasone can be increased when it is combined with Nomegestrol.Approved
Nomegestrol acetateThe serum concentration of Nomegestrol acetate can be decreased when it is combined with Dexamethasone.Approved, Investigational
NorelgestrominThe serum concentration of Dexamethasone can be increased when it is combined with Norelgestromin.Approved, Investigational
NorepinephrineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Norepinephrine.Approved
NorethisteroneThe serum concentration of Dexamethasone can be increased when it is combined with Norethisterone.Approved
NorethynodrelThe serum concentration of Norethynodrel can be decreased when it is combined with Dexamethasone.Approved
NorfloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Dexamethasone can be increased when it is combined with Norgestimate.Approved, Investigational
NorgestrelThe serum concentration of Dexamethasone can be increased when it is combined with Norgestrel.Approved
NorgestrienoneThe serum concentration of Dexamethasone can be increased when it is combined with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Dexamethasone.Approved
NS-398The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with NS-398.Experimental
NylidrinThe serum concentration of Nylidrin can be decreased when it is combined with Dexamethasone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ocrelizumab.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Dexamethasone.Investigational
OfloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ofloxacin.Approved
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Dexamethasone.Approved
OlodaterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Olodaterol.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Dexamethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone.Approved
OmarigliptinThe therapeutic efficacy of Omarigliptin can be decreased when used in combination with Dexamethasone.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dexamethasone.Approved, Investigational
OmeprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Dexamethasone.Approved
ONT-093The serum concentration of Dexamethasone can be increased when it is combined with ONT-093.Investigational
OpiumThe serum concentration of Opium can be decreased when it is combined with Dexamethasone.Approved, Illicit
OrbifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Orciprenaline.Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Dexamethasone.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
OtiloniumThe serum concentration of Otilonium can be decreased when it is combined with Dexamethasone.Experimental, Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dexamethasone.Approved, Investigational
OxandroloneThe risk or severity of fluid retention can be increased when Dexamethasone is combined with Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Oxaprozin.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Dexamethasone.Approved
Oxolinic acidThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Oxolinic acid.Experimental
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Dexamethasone.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
OxymetholoneThe risk or severity of fluid retention can be increased when Dexamethasone is combined with Oxymetholone.Approved, Illicit
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexamethasone.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone.Approved, Investigational
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Dexamethasone.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Dexamethasone.Approved, Investigational
PancuroniumThe risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Dexamethasone.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Dexamethasone can be increased when it is combined with Pantoprazole.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Dexamethasone.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Paramethasone.Approved
ParaoxonThe therapeutic efficacy of Paraoxon can be decreased when used in combination with Dexamethasone.Experimental
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Dexamethasone.Approved
ParicalcitolThe therapeutic efficacy of Paricalcitol can be decreased when used in combination with Dexamethasone.Approved, Investigational
ParitaprevirThe serum concentration of Dexamethasone can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Dexamethasone can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.Approved
PazufloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexamethasone.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Dexamethasone.Approved, Investigational
PenfluridolThe serum concentration of Penfluridol can be decreased when it is combined with Dexamethasone.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Dexamethasone.Approved, Investigational
PentazocineThe serum concentration of Dexamethasone can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Dexamethasone.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Dexamethasone.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Dexamethasone.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Dexamethasone.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Dexamethasone.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be decreased when it is combined with Dexamethasone.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Dexamethasone.Approved
PethidineThe serum concentration of Dexamethasone can be increased when it is combined with Pethidine.Approved
PF-00610355The risk or severity of hypokalemia can be increased when Dexamethasone is combined with PF-00610355.Investigational
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Dexamethasone.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Dexamethasone can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Dexamethasone.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Dexamethasone.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Dexamethasone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone.Approved
PhenylbutazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Phenylbutazone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Dexamethasone.Approved, Investigational
PhenylpropanolamineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Dexamethasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Dexamethasone.Approved, Investigational
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Dexamethasone.Approved, Investigational
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Dexamethasone.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Dexamethasone can be increased when it is combined with Pimozide.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Dexamethasone.Approved
PinaveriumThe serum concentration of Pinaverium can be decreased when it is combined with Dexamethasone.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational
PipecuroniumThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Dexamethasone.Approved
Pipemidic acidThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Pipemidic acid.Experimental
PiperaquineThe serum concentration of Piperaquine can be decreased when it is combined with Dexamethasone.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Dexamethasone.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pirarubicin.Investigational
PirbuterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Pirbuterol.Approved
PiretanideThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pirfenidone.Approved, Investigational
Piromidic acidThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dexamethasone.Approved
PitolisantThe serum concentration of Dexamethasone can be decreased when it is combined with Pitolisant.Approved, Investigational
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Dexamethasone.Approved
PolythiazideDexamethasone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dexamethasone.Approved
PonatinibThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Dexamethasone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pralatrexate.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Dexamethasone.Approved, Investigational
PranoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of edema formation can be increased when Prasterone is combined with Dexamethasone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of edema formation can be increased when Prasterone sulfate is combined with Dexamethasone.Investigational
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Dexamethasone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dexamethasone.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Dexamethasone.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dexamethasone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Dexamethasone.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Prednylidene.Experimental
PregabalinThe serum concentration of Pregabalin can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Dexamethasone.Approved, Experimental, Investigational
PrenylamineThe serum concentration of Prenylamine can be decreased when it is combined with Dexamethasone.Withdrawn
PrimaquineThe serum concentration of Dexamethasone can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Dexamethasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dexamethasone.Approved, Investigational
ProcaterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Procaterol.Approved, Investigational
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ProgesteroneThe serum concentration of Dexamethasone can be increased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Proglumetacin.Experimental
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Dexamethasone.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
PromegestoneThe serum concentration of Promegestone can be decreased when it is combined with Dexamethasone.Experimental
PromethazineThe serum concentration of Dexamethasone can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Propacetamol.Approved, Investigational
PropafenoneThe serum concentration of Dexamethasone can be increased when it is combined with Propafenone.Approved
PropiverineThe serum concentration of Propiverine can be decreased when it is combined with Dexamethasone.Approved, Investigational
PropofolThe serum concentration of Dexamethasone can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Dexamethasone.Approved, Investigational
PropylthiouracilThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Propylthiouracil.Approved, Investigational
PropyphenazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Proquazone.Experimental
ProtokylolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Prulifloxacin.Investigational
PyrantelThe risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Dexamethasone.Approved, Vet Approved
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Dexamethasone.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dexamethasone.Approved, Investigational
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Dexamethasone.Approved, Illicit
QuercetinThe serum concentration of Dexamethasone can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.Approved
QuinacrineThe serum concentration of Dexamethasone can be increased when it is combined with Quinacrine.Approved, Investigational
QuinethazoneDexamethasone may increase the hypokalemic activities of Quinethazone.Approved
QuingestanolThe serum concentration of Dexamethasone can be increased when it is combined with Quingestanol.Experimental
QuinidineThe serum concentration of Dexamethasone can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Dexamethasone can be decreased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexamethasone.Approved, Investigational
RacepinephrineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Racepinephrine.Approved
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Dexamethasone.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Raltitrexed.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Dexamethasone.Approved, Investigational
RanitidineThe serum concentration of Dexamethasone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Dexamethasone.Approved, Investigational
RapacuroniumThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Dexamethasone.Withdrawn
ReboxetineThe serum concentration of Dexamethasone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Dexamethasone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Dexamethasone.Approved, Investigational
ReserpineThe serum concentration of Dexamethasone can be increased when it is combined with Reserpine.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Dexamethasone.Approved
Reversin 121The serum concentration of Dexamethasone can be increased when it is combined with Reversin 121.Experimental
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Dexamethasone.Approved, Investigational
RifampicinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Dexamethasone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Dexamethasone can be decreased when it is combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Dexamethasone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Dexamethasone.Approved
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Dexamethasone.Approved, Investigational
RimexoloneThe serum concentration of Dexamethasone can be decreased when it is combined with Rimexolone.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Dexamethasone.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dexamethasone.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dexamethasone.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Dexamethasone.Approved, Investigational
RitodrineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Dexamethasone can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Dexamethasone.Approved
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dexamethasone.Approved, Investigational
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Dexamethasone.Experimental, Investigational
RobenacoxibThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Robenacoxib.Experimental, Vet Approved
RocuroniumThe risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Dexamethasone.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Dexamethasone.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Dexamethasone.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Ronifibrate.Experimental
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Dexamethasone.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Dexamethasone.Approved, Investigational
RosoxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dexamethasone.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Dexamethasone.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Dexamethasone.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Dexamethasone.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Dexamethasone.Approved, Investigational
RufloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Rufloxacin.Experimental
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Dexamethasone.Approved
RuxolitinibThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ruxolitinib.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Dexamethasone.Approved, Investigational
SalbutamolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Dexamethasone can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Salmeterol.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Dexamethasone.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Dexamethasone.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Dexamethasone.Approved
SalsalateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Salsalate.Approved
SaquinavirThe metabolism of Dexamethasone can be decreased when combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Dexamethasone.Approved
SC-236The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with SC-236.Experimental, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Dexamethasone.Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
SeletracetamThe serum concentration of Seletracetam can be decreased when it is combined with Dexamethasone.Investigational
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Dexamethasone.Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be decreased when used in combination with Dexamethasone.Approved, Investigational
SeocalcitolThe therapeutic efficacy of Seocalcitol can be decreased when used in combination with Dexamethasone.Experimental, Investigational
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Dexamethasone.Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Dexamethasone can be increased when it is combined with Sertraline.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Dexamethasone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Dexamethasone.Approved
SiltuximabThe serum concentration of Dexamethasone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Dexamethasone.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Dexamethasone is combined with Simfibrate.Experimental
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Dexamethasone is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Dexamethasone.Approved, Investigational
SitafloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Dexamethasone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Dexamethasone can be decreased when combined with Sodium bicarbonate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Dexamethasone.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Dexamethasone.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Dexamethasone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Dexamethasone.Investigational
SparfloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sparfloxacin.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Dexamethasone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Dexamethasone.Investigational
St. John's WortThe serum concentration of Dexamethasone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe risk or severity of edema formation can be increased when Stanolone is combined with Dexamethasone.Illicit, Investigational
StanozololThe risk or severity of fluid retention can be increased when Dexamethasone is combined with Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Dexamethasone can be increased when it is combined with Staurosporine.Experimental
SteproninThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Stepronin.Approved
StiripentolThe serum concentration of Dexamethasone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Dexamethasone.Approved, Investigational
SuccinylcholineThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Dexamethasone.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.Approved, Investigational
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Dexamethasone.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Dexamethasone.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Dexamethasone.Approved, Vet Approved
SulindacThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Sulindac.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Dexamethasone.Approved, Investigational
SuprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Suprofen.Approved, Withdrawn
SuvorexantThe serum concentration of Dexamethasone can be increased when it is combined with Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dexamethasone.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dexamethasone.Approved
TacalcitolThe therapeutic efficacy of Tacalcitol can be decreased when used in combination with Dexamethasone.Experimental, Investigational
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Dexamethasone.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Dexamethasone.Approved, Investigational
TalniflumateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Dexamethasone.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Dexamethasone.Approved, Investigational
TariquidarThe serum concentration of Dexamethasone can be increased when it is combined with Tariquidar.Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Dexamethasone.Approved
TaspoglutideThe therapeutic efficacy of Taspoglutide can be decreased when used in combination with Dexamethasone.Investigational
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Dexamethasone.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Dexamethasone.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tedizolid phosphate.Approved
TelaprevirThe metabolism of Dexamethasone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Dexamethasone can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Dexamethasone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Temafloxacin.Withdrawn
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Dexamethasone.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Dexamethasone.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Temsirolimus.Approved
TeneligliptinThe therapeutic efficacy of Teneligliptin can be decreased when used in combination with Dexamethasone.Investigational
TenidapThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tenidap.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Dexamethasone.Approved
TenoxicamThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tepoxalin.Vet Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Terbutaline.Approved
TerfenadineThe serum concentration of Dexamethasone can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Dexamethasone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone.Approved
TerodilineThe serum concentration of Terodiline can be decreased when it is combined with Dexamethasone.Experimental
TesmilifeneThe serum concentration of Dexamethasone can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of edema formation can be increased when Testosterone is combined with Dexamethasone.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Dexamethasone.Approved
Testosterone enantate benzilic acid hydrazoneThe risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Dexamethasone.Approved, Experimental
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Dexamethasone.Approved
Testosterone propionateThe risk or severity of edema formation can be increased when Testosterone propionate is combined with Dexamethasone.Approved, Investigational, Vet Approved, Withdrawn
Testosterone succinateThe risk or severity of edema formation can be increased when Testosterone succinate is combined with Dexamethasone.Experimental
Testosterone undecanoateThe risk or severity of edema formation can be increased when Testosterone undecanoate is combined with Dexamethasone.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
TetrahydropalmatineThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Dexamethasone.Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tetrandrine.Experimental
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Dexamethasone.Approved, Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Dexamethasone.Investigational
ThalidomideThe risk or severity of thromboembolism can be increased when Dexamethasone is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dexamethasone.Approved
ThiamylalThe serum concentration of Thiamylal can be decreased when it is combined with Dexamethasone.Approved, Vet Approved
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Dexamethasone.Approved, Investigational
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Dexamethasone.Approved, Investigational
TianeptineThe serum concentration of Tianeptine can be decreased when it is combined with Dexamethasone.Approved, Investigational
Tiaprofenic acidThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Dexamethasone.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Dexamethasone.Approved, Investigational
TinoridineThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tinoridine.Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Dexamethasone.Approved
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Dexamethasone.Approved
TipifarnibThe serum concentration of Dexamethasone can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Dexamethasone can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe serum concentration of Tocofersolan can be decreased when it is combined with Dexamethasone.Approved
TocopherolThe serum concentration of Tocopherol can be decreased when it is combined with Dexamethasone.Approved, Investigational
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Dexamethasone.Approved, Investigational
TofacitinibDexamethasone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dexamethasone.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.Approved, Investigational
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Dexamethasone.Approved, Investigational
TolmetinThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Tolmetin.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Dexamethasone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dexamethasone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dexamethasone.Approved, Investigational
TorasemideThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Torasemide.Approved
ToremifeneThe serum concentration of Dexamethasone can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trabectedin.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Dexamethasone.Approved, Investigational
TranilastThe serum concentration of Tranilast can be decreased when it is combined with Dexamethasone.Approved, Investigational
TrastuzumabThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trastuzumab emtansine.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.Approved, Investigational
TrestoloneThe risk or severity of edema formation can be increased when Trestolone is combined with Dexamethasone.Investigational
Trestolone acetateThe risk or severity of edema formation can be increased when Trestolone acetate is combined with Dexamethasone.Experimental
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Dexamethasone.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Dexamethasone.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Dexamethasone.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Dexamethasone.Vet Approved
TrichlormethiazideDexamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Dexamethasone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimebutineThe serum concentration of Trimebutine can be decreased when it is combined with Dexamethasone.Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Dexamethasone.Approved
TrimethoprimThe serum concentration of Dexamethasone can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Dexamethasone.Approved
TriptolideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Trofosfamide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Dexamethasone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone.Approved
TroleandomycinThe metabolism of Dexamethasone can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of myopathy and weakness can be increased when Tubocurarine is combined with Dexamethasone.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Dexamethasone.Approved
TyrothricinThe therapeutic efficacy of Tyrothricin can be decreased when used in combination with Dexamethasone.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Dexamethasone.Approved, Investigational
UlipristalThe serum concentration of Dexamethasone can be increased when it is combined with Ulipristal.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Ulobetasol.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Dexamethasone.Approved, Investigational
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Dexamethasone.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Dexamethasone can be increased when it is combined with Valinomycin.Experimental
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Dexamethasone.Approved, Investigational
ValspodarThe serum concentration of Dexamethasone can be increased when it is combined with Valspodar.Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Dexamethasone.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Dexamethasone.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Dexamethasone.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Dexamethasone.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Dexamethasone.Approved
VecuroniumThe risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Dexamethasone.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Dexamethasone.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Dexamethasone.Approved, Investigational
VemurafenibThe serum concentration of Dexamethasone can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Dexamethasone.Approved, Investigational
VenlafaxineThe serum concentration of Dexamethasone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Dexamethasone can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Dexamethasone.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dexamethasone.Approved, Investigational
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Dexamethasone.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Vilanterol.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Dexamethasone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Dexamethasone.Approved
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Dexamethasone.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be decreased when it is combined with Dexamethasone.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Dexamethasone.Approved, Investigational
VinpocetineThe serum concentration of Vinpocetine can be decreased when it is combined with Dexamethasone.Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Dexamethasone.Approved, Investigational
Vitamin DThe therapeutic efficacy of Vitamin D can be decreased when used in combination with Dexamethasone.Approved, Nutraceutical, Vet Approved
VoacamineThe serum concentration of Dexamethasone can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Dexamethasone.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Dexamethasone.Approved, Investigational
VorapaxarThe serum concentration of Dexamethasone can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Dexamethasone can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Vorinostat.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Dexamethasone.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Dexamethasone.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Dexamethasone.Approved
WIN 55212-2The serum concentration of WIN 55212-2 can be decreased when it is combined with Dexamethasone.Experimental
WortmanninThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Wortmannin.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Dexamethasone.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Dexamethasone.Approved, Investigational
YohimbineThe serum concentration of Dexamethasone can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Dexamethasone.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Dexamethasone.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Dexamethasone.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Zaltoprofen.Approved, Investigational
ZiconotideThe serum concentration of Ziconotide can be decreased when it is combined with Dexamethasone.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Zidovudine.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Dexamethasone.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Dexamethasone.Approved
ZomepiracThe serum concentration of Dexamethasone can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Dexamethasone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Dexamethasone.Approved
ZosuquidarThe serum concentration of Dexamethasone can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe serum concentration of Zotepine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.

References

Synthesis Reference

Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015364
KEGG Drug
D00292
KEGG Compound
C15643
PubChem Compound
5743
PubChem Substance
46508930
ChemSpider
5541
BindingDB
18207
ChEBI
41879
ChEMBL
CHEMBL384467
Therapeutic Targets Database
DAP000007
PharmGKB
PA449247
IUPHAR
2768
Guide to Pharmacology
GtP Drug Page
HET
DEX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Dexamethasone
ATC Codes
R01AD03 — DexamethasoneS03CA01 — Dexamethasone and antiinfectivesS02CA06 — Dexamethasone and antiinfectivesC05AA09 — DexamethasoneS01BA01 — DexamethasoneS01CB01 — DexamethasoneH02AB02 — DexamethasoneA01AC02 — DexamethasoneD10AA03 — DexamethasoneS02BA06 — DexamethasoneD07XB05 — DexamethasoneD07AB19 — DexamethasoneD07CB04 — Dexamethasone and antibioticsS03BA01 — DexamethasoneS01CA01 — Dexamethasone and antiinfectivesR01AD53 — Dexamethasone, combinations
AHFS Codes
  • 68:04.00 — Adrenals
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
PDB Entries
1m2z / 1p93 / 3gn8 / 3mne / 3mno / 3mnp / 4uda / 4udc
FDA label
Download (96 KB)
MSDS
Download (74.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceMultiple Myeloma (MM)1
0Active Not RecruitingBasic SciencePlasma Cell Myeloma1
0CompletedSupportive CareNausea / Vomiting1
0CompletedTreatmentImpacted Third Molar Tooth1
0CompletedTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
0Enrolling by InvitationPreventionDistal Radius Fractures / Osteoarthritis (OA)1
0Not Yet RecruitingPreventionSurgery, Hand1
0RecruitingBasic ScienceHealthy Volunteers1
0RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Non Hodgkin's Lymphoma / Pre B-Cell Acute Lymphoblastic Leukaemia1
0RecruitingTreatmentCesarean Section1
0RecruitingTreatmentOral Lichen Planus1
0TerminatedTreatmentMultiple Myeloma (MM)1
0TerminatedTreatmentRecurrent Cutaneous T-cell lymphoma / Refractory T-Cell Lymphoma / T-Cell Lymphomas1
0WithdrawnBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome1
1Active Not RecruitingOtherMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentCholangiocellular Carcinoma) (ICC) / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
1Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
1Active Not RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentHigh Risk Smoldering Multiple Myeloma / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentImpaired Renal Function / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
1Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute T-cell / Precursor T-Cell Lymphoblastic Lymphoma1
1Active Not RecruitingTreatmentLymphoma, Hodgkins / Refractory / Relapses1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Peripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)11
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentPlasma Cell Myeloma4
1Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1Active Not RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
1CompletedNot AvailablePostoperative pain1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceStress1
1CompletedDiagnosticCaudal Block1
1CompletedDiagnosticHealthy Volunteers / Lean1
1CompletedDiagnosticPulmonary Nodules1
1CompletedHealth Services ResearchCoarctation of the Aorta1
1CompletedOtherMultiple Myeloma (MM)1
1CompletedPreventionHealthy Volunteers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedPreventionLacrimation increased1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAcute Lymphoid Leukemia Relapse / Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant1
1CompletedTreatmentAdvanced Cancer, Various, NOS1
1CompletedTreatmentAdvanced Malignancies / Cancer, Advanced1
1CompletedTreatmentAll / Blast Crisis / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / Smith-Magenis Syndrome1
1CompletedTreatmentAmyloidosis / Systemic Light Chain Amyloidosis1
1CompletedTreatmentBronchiolitis1
1CompletedTreatmentCancers1
1CompletedTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma1
1CompletedTreatmentColorectal Cancers / Metastatic Cancers1
1CompletedTreatmentEye Dryness1
1CompletedTreatmentGraves' Disease1
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHepatic Insufficiency / Neoplasm Metastases1
1CompletedTreatmentHodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Waldenström's Macroglobulinemia (WM)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemia, Acute / Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias2
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLymphoma, Low-Grade / Lymphoma, Mixed-Cell, Follicular / Lymphoma, Small Cleaved-Cell, Follicular / Small Lymphocytic Lymphoma (SLL)1
1CompletedTreatmentMalignancies / Neoplasms1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMesothelioma1
1CompletedTreatmentMultiple Myeloma (MM)15
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentNeoplasms / Neoplasms by Histologic Type / Neoplasms, Connective and Soft Tissue / Sarcomas / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentNon-infectious, Non-necrotizing Anterior Scleritis1
1CompletedTreatmentPain1
1CompletedTreatmentPlasma Cell Myeloma1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRecurrent Plasma Cell Myeloma1
1CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1CompletedTreatmentTumors1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentVitrectomy therapy1
1CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
1Enrolling by InvitationTreatmentMyelodysplastic Syndromes1
1Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / All / ALL, Childhood1
1Not Yet RecruitingTreatmentHigh Altitude Cerebral Edema1
1Not Yet RecruitingTreatmentLeukemia, Plasma Cell1
1Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1RecruitingBasic ScienceSleep Restriction1
1RecruitingOtherBlood Component Removal / Blood Donors / Granulocyte Colony-Stimulation Factor / Leukocyte Transfusion1
1RecruitingPreventionMigraines1
1RecruitingTreatmentAL Amyloidosis1
1RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Refractory Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hematopoietic/Lymphoid Cancer / Leukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAcute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse1
1RecruitingTreatmentAdnexal Masses / Borderline Ovarian Epithelial Tumor / Neoplasms, Ovarian / Ovarian Clear Cell Tumor / Ovarian Endometrioid Tumor / Ovarian Serous Tumor / Recurrent Ovarian Carcinoma1
1RecruitingTreatmentAmyloid Light Chain (AL) Amyloidosis / Hematopoietic/Lymphoid Cancer1
1RecruitingTreatmentAnemias / Hypercalcemia / Lytic Bone Lesion / Osteopenia / Pathologic fracture / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1RecruitingTreatmentCancer, Breast / Prostate Cancer1
1RecruitingTreatmentCholangiocarcinomas / Neoplasms, Hepatic1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentDiseases of Oesophagus Stomach and Duodenum1
1RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentLeptomeningeal Metastases1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMild -Moderate Anaphylaxis - Symptoms That Affect the Skin With Cardiovascular, Respiratory or Gastrointestinal Involvement, But no Signs of Hypotension ,Laryng1
1RecruitingTreatmentMultiple Myeloma (MM)6
1RecruitingTreatmentMultiple Myeloma (MM) / Relapsed and/or Refractory Multiple Myeloma1
1RecruitingTreatmentNeoplasms Malignant1
1RecruitingTreatmentRecurrent B Acute Lymphoblastic Leukemia / Refractory B Acute Lymphoblastic Leukemia1
1RecruitingTreatmentRefractory Multiple Myeloma1
1RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
1RecruitingTreatmentRetinoblastoma1
1RecruitingTreatmentStatus Asthmaticus1
1RecruitingTreatmentTumors, Solid1
1SuspendedTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Central Nervous System Lymphoma / Intraocular Lymphoma / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Recurrent Adult Diffuse Large Cell Lymphoma / Retinal Lymphoma1
1SuspendedTreatmentCongestive Heart Failure (CHF)1
1SuspendedTreatmentHypercalcemia / Plasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1SuspendedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1SuspendedTreatmentRecurrent Plasma Cell Myeloma1
1TerminatedTreatmentAcute Lymphoblastic Leukaemia Recurrent / Allergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood Infratentorial Ependymoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Gonadotroph Adenoma / Pituitary Basophilic Adenoma / Pituitary Chromophobe Adenoma / Pituitary Eosinophilic Adenoma / Prolactin Secreting Adenoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Pituitary Tumor / Recurrent/Refractory Childhood Hodgkin Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / TSH Secreting Adenoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentLeukemias1
1TerminatedTreatmentLymphoid Hematological Malignancies / Multiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed and Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1TerminatedTreatmentMultiple Myeloma (MM)5
1TerminatedTreatmentPlasma Cell Myeloma2
1TerminatedTreatmentRecurrent Childhood Anaplastic Astrocytoma / Recurrent Childhood Anaplastic Oligoastrocytoma / Recurrent Childhood Anaplastic Oligodendroglioma / Recurrent Childhood Giant Cell Glioblastoma / Recurrent Childhood Glioblastoma / Recurrent Childhood Gliomatosis Cerebri / Recurrent Childhood Gliosarcoma1
1TerminatedTreatmentRotator Cuff Syndrome1
1TerminatedTreatmentWaldenström's Macroglobulinemia (WM)1
1TerminatedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
1Unknown StatusTreatmentLateral Epicondylitis (Tennis Elbow)1
1WithdrawnTreatmentMalignant Lymphomas1
1WithdrawnTreatmentMalignant Lymphomas / Neoplasms, Brain / Sarcoma, Osteogenic / Sarcomas / Wilms' tumor1
1WithdrawnTreatmentMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic / Multiple Myeloma (MM)1
1WithdrawnTreatmentMultiple Myeloma (MM)1
1WithdrawnTreatmentTraumas1
1, 2Active Not RecruitingTreatmentAL Amyloidosis1
1, 2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphocytic Leukemia (ALL)1
1, 2Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced / Metastatic Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentCancer of the Ovary / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Lymphomas / Multiple Myeloma (MM) / Renal Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentCognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Therapy-Related Toxicity / Tiredness / Waldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentEsophageal Cancers1
1, 2Active Not RecruitingTreatmentKahler Disease / Multiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)24
1, 2Active Not RecruitingTreatmentPlasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma3
1, 2Active Not RecruitingTreatmentRelapsed and/or Relapsed-refractory Multiple Myeloma1
1, 2Active Not RecruitingTreatmentT-cell Acute Lymphoblastic Leukemia / T-cell Lymphoblastic Lymphoma1
1, 2CompletedSupportive CareNeovascular Age-Related Macular Degeneration1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentBranch Retinal Vein Occlusion / Macular Degeneration / Macular Edema (ME)1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentDiabetic Macular Edema (DME)1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMultiple Myeloma (MM)8
1, 2CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentPatients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal1
1, 2CompletedTreatmentPlasma Cell Myeloma3
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2Not Yet RecruitingTreatmentAmyloidosis1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAmyloidosis / Plasma Cell Myeloma1
1, 2RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma1
1, 2RecruitingTreatmentGeneral Surgery / Pelvic Organ Prolapse (POP) / Postoperative pain1
1, 2RecruitingTreatmentHaematological Malignancies1
1, 2RecruitingTreatmentLeptomeningeal Metastasis1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome1
1, 2RecruitingTreatmentLeukemias1
1, 2RecruitingTreatmentLung Cancers1
1, 2RecruitingTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentMigraines1
1, 2RecruitingTreatmentMultiple Myeloma (MM)11
1, 2RecruitingTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed/Refractory Multiple Myeloma1
1, 2RecruitingTreatmentMultiple Myeloma in Relapse1
1, 2RecruitingTreatmentPlasma Cell Myeloma2
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / T(11;14)1
1, 2RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
1, 2RecruitingTreatmentTreatments1
1, 2SuspendedTreatmentIndolent Plasma Cell Myeloma / Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2SuspendedTreatmentLoss of Chromosome 17p / Recurrent Plasma Cell Myeloma1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentMacular Edema (ME)1
1, 2TerminatedTreatmentMultiple Myeloma (MM)6
1, 2TerminatedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1, 2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2TerminatedTreatmentPlasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Unknown StatusPreventionTonsillectomy1
1, 2Unknown StatusTreatmentAmyloidosis1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)4
1, 2Unknown StatusTreatmentSwallowing1
1, 2WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2WithdrawnTreatmentMelanoma1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)3
2Active Not RecruitingTreatmentAL Amyloidosis1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAdvanced Cancers / Haematological disorders / Tumors, Solid1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAmyloidosis1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
2Active Not RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma of Mucosa-Associated Lymphoid Tissue / MALT Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentLabour1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
2Active Not RecruitingTreatmentLiver Cancer1
2Active Not RecruitingTreatmentLung Cancers / Neoplasms Metastasis1
2Active Not RecruitingTreatmentLymphoma, Hodgkins1
2Active Not RecruitingTreatmentLymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentMalignant Lymphomas3
2Active Not RecruitingTreatmentMultiple Myeloma (MM)37
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Relapse After Use of Lenalidomide and Bortezomib1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Neurotoxicity1
2Active Not RecruitingTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentNeoplasms Metastasis1
2Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentPrior Bortezomib Therapy Acceptable / Waldenstroms1
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2Active Not RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma1
2Active Not RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Myeloma1
2Active Not RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma3
2Active Not RecruitingTreatmentSteroids In Management Of Acute Asthma Exacerbations1
2Active Not RecruitingTreatmentT-Cell Lymphomas1
2Active Not RecruitingTreatmentTumors, Solid1
2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
2CompletedPreventionCINV1
2CompletedPreventionCancers1
2CompletedPreventionDiabetes Mellitus (DM) / Macular Edema (ME) / Pseudophakia1
2CompletedPreventionEffects of; Anesthesia, in Labor and Delivery1
2CompletedPreventionNausea and Vomiting, Postoperative1
2CompletedPreventionPostspinal Shivering1
2CompletedPreventionSuspected Appendicitis1
2CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedSupportive CareColorectal Cancers / Nausea and Vomiting1
2CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas1
2CompletedSupportive CareMalignant Lymphomas / Myeloma, Plasma-Cell1
2CompletedSupportive CareNausea / Vomiting1
2CompletedSupportive CarePain1
2CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
2CompletedTreatmentACTH / Cortisol Resistance / Glucocorticoid therapy / Mineralcorticoid / Negative Feedback1
2CompletedTreatmentAcute Anterior Uveitis1
2CompletedTreatmentAcute Gouty Arthritis1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Hepatic Metastases / Metastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdrenal Hyperplasia, Congenital1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
2CompletedTreatmentAdvanced Solid Tumors1
2CompletedTreatmentAge Related Macular Degeneration (ARMD)1
2CompletedTreatmentAmyloidosis2
2CompletedTreatmentAnterior Uveitis (AU)1
2CompletedTreatmentAnterior chamber inflammation / Cataracts / Postoperative pain1
2CompletedTreatmentBlast Crisis / Chronic Myeloid Leukemia (CML) / Leukemia, Lymphocytic, Acute / Philadelphia Chromosome1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer of the Ovary1
2CompletedTreatmentCancer of the Ovary / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCataracts1
2CompletedTreatmentChemotherapy-Induced / Nausea and Vomiting1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers1
2CompletedTreatmentConjunctivitis, Seasonal Allergic2
2CompletedTreatmentContiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Marginal Zone Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentDiabetes Mellitus (DM) / Diabetic Macular Edema (DME) / Retinopathy, Diabetic1
2CompletedTreatmentDiabetic Macular Edema (DME)2
2CompletedTreatmentDiabetic Macular Edema (DME) / Vitrectomy therapy1
2CompletedTreatmentDisease, Adnexal / Endocrine Gland Neoplasms / Genital Diseases, Female / Neoplasms / Neoplasms by Site / Neoplasms, Ovarian / Ovarian Diseases1
2CompletedTreatmentDry Eye Syndrome (DES)1
2CompletedTreatmentEar Diseases / Otitis / Otitis Externa / Otorhinolaryngologic Diseases1
2CompletedTreatmentEmpyema / Parapneumonic Pleural Effusion1
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentGenetic Syndrome / Nervous System Disorders1
2CompletedTreatmentGenital Neoplasms, Female Urogenital Neoplasms / Neoplasms, Endometrial / Uterine Neoplasms1
2CompletedTreatmentGlomerulonephritis / Glomerulonephritis minimal lesion1
2CompletedTreatmentHard of Hearing1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentHematologic Cancers1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentImmune Thrombocytopenia1
2CompletedTreatmentImmune Thrombocytopenic Purpura ( ITP )2
2CompletedTreatmentLeiomyosarcomas / Liposarcoma1
2CompletedTreatmentLeukemia, Lymphocytic, Acute1
2CompletedTreatmentLeukemias10
2CompletedTreatmentLeukemias / Malignant Lymphomas4
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentMacular Degeneration / Subfoveal Choroidal Neovascularization1
2CompletedTreatmentMacular Edema (ME)1
2CompletedTreatmentMacular Edema (ME) / Retinopathy, Diabetic1
2CompletedTreatmentMacular Edema After Cataract Surgery in Patients With Diabetes Mellitus1
2CompletedTreatmentMaculopathies, Age-Related / Subfoveal Choroidal Neovascularization2
2CompletedTreatmentMalignant Lymphomas18
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMantle Cell Lymphoma (MCL)2
2CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
2CompletedTreatmentMultiple Myeloma (MM)45
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
2CompletedTreatmentMultiple Myeloma (MM) / Renal Failure1
2CompletedTreatmentMultiple Myeloma (MM) / Renal Insuficiency1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm19
2CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentMyxoid Liposarcoma1
2CompletedTreatmentNasal Type Extranodal NK/T-Cell Lymphoma1
2CompletedTreatmentNasopharyngeal Carcinoma1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentOral Chronic Graft-Versus-Host Disease1
2CompletedTreatmentOral Lichen Planus1
2CompletedTreatmentPOEMS Syndrome2
2CompletedTreatmentPemphigus1
2CompletedTreatmentPlasma Cell Myeloma2
2CompletedTreatmentPrimary Amyloidosis of Light Chain Type1
2CompletedTreatmentPrimary Plasma Cell Leukemia1
2CompletedTreatmentPrimary Systemic Amyloidosis2
2CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma2
2CompletedTreatmentSj(SqrRoot)(Delta)Gren s Syndrome / Xerostomia1
2CompletedTreatmentSpinal Cord Compression From Neoplasm Metastasis1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentWaldenström's Macroglobulinemia (WM)3
2CompletedTreatmentWet Macular Degeneration1
2CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting2
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Not Yet RecruitingSupportive CareCaudal Block1
2Not Yet RecruitingSupportive CareLung Cancers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
2Not Yet RecruitingTreatmentApophysitis; Juvenile1
2Not Yet RecruitingTreatmentBronchiolitis1
2Not Yet RecruitingTreatmentChronic Subdural Hematomas1
2Not Yet RecruitingTreatmentDexamethasone / Inflammatory Bowel Diseases (IBD) / Postoperative Complications / Postoperative paralytic ileus1
2Not Yet RecruitingTreatmentFocus of Study / Thrombocytopenias1
2Not Yet RecruitingTreatmentHematopoietic/Lymphoid Cancer / Mantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Lymphomas1
2Not Yet RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)6
2Not Yet RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2Not Yet RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma Progression / Refractory Multiple Myeloma1
2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentOvarian Hyperstimulation Syndrome1
2Not Yet RecruitingTreatmentPlasma Cell Myeloma1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma2
2Not Yet RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
2Not Yet RecruitingTreatmentSmoldering Multiple Myeloma (SMM)1
2Not Yet RecruitingTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingPreventionPostoperative pain1
2RecruitingSupportive CareAdvanced Cancers1
2RecruitingSupportive CareMultiple Myeloma (MM)2
2RecruitingSupportive CareSarcomas1
2RecruitingTreatmentAL Amyloidosis1
2RecruitingTreatmentALL (Acute Lymphoblastic Leukemia) / B-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias2
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / Ann Arbor Stage II Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentBladder Cancers / Urothelial Cancer1
2RecruitingTreatmentCancer - Multiple Myeloma / Multiple Myeloma (MM)1
2RecruitingTreatmentCardiac Amyloidosis1
2RecruitingTreatmentCervicgenic Upper Extremity Radiculopathy1
2RecruitingTreatmentCholangiocellular Carcinoma / Cholangiolar Carcinoma / Intrahepatic Cholangiocarcinoma / Peripheral Cholangiocarcinoma1
2RecruitingTreatmentChronic Kidney Disease (CKD) / Multiple Myeloma (MM)1
2RecruitingTreatmentChronic Limb Ischemia2
2RecruitingTreatmentChronic Lung Disease of Prematurity1
2RecruitingTreatmentColorectal Adenocarcinoma Metastatic to the Liver1
2RecruitingTreatmentExtranodal NK-T-CELL LYMPHOMA / NK/T Cell Lymphoma1
2RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentHNSCC / HPV-Related Squamous Cell Carcinoma1
2RecruitingTreatmentHead Neck Cancer / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
2RecruitingTreatmentHeavy Menstrual Bleeding1
2RecruitingTreatmentHematopoietic/Lymphoid Cancer / Richter's Transformation1
2RecruitingTreatmentHenoch-Schoenlein Purpura (HSP)1
2RecruitingTreatmentImmune Thrombocytopenia2
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemia, Plasma Cell / Plasma Cell Myeloma / Plasmacytoma1
2RecruitingTreatmentLeukemias6
2RecruitingTreatmentLichen Planus (LP)1
2RecruitingTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentLymphoma, Lymphoblastic1
2RecruitingTreatmentLymphoplasmacytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentMalignant Lymphomas3
2RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2RecruitingTreatmentMultiple Myeloma (MM)32
2RecruitingTreatmentMultiple Myeloma (MM) / Relapsed/Refractory1
2RecruitingTreatmentMultiple Myeloma in Relapse2
2RecruitingTreatmentNausea and Vomiting, Postoperative / Quality of Recovery / Same Day Surgery / Vaginal Prolapse1
2RecruitingTreatmentNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
2RecruitingTreatmentPOEMS Syndrome1
2RecruitingTreatmentPlasmacytoma / POEMS Syndrome1
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2RecruitingTreatmentPlasma Cell Myeloma3
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2RecruitingTreatmentPulmonary Fibrosis1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma3
2RecruitingTreatmentRecurrent Primary Amyloidosis1
2RecruitingTreatmentRefractory Multiple Myeloma2
2RecruitingTreatmentRelapse and / or Refractory Myeloma1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma2
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM)1
2RecruitingTreatmentSudden Sensorineural Hearing Loss (SSNHL)1
2SuspendedTreatmentHead and Neck Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2SuspendedTreatmentMalignant Lymphomas1
2SuspendedTreatmentSmoldering Multiple Myeloma (SMM)1
2TerminatedPreventionNausea / Vomiting1
2TerminatedSupportive CareBrain Cancer1
2TerminatedSupportive CareNausea and Vomiting / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2TerminatedSupportive CareNausea / Unspecified Childhood Solid Tumor, Protocol Specific / Vomiting1
2TerminatedTreatmentAcute Adenoviral Conjunctivitis1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAcute Otitis Media1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCancer, Breast / Lung Cancers1
2TerminatedTreatmentCancers / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCorneal Infiltrates1
2TerminatedTreatmentCystoid Macular Edema / Macular Edema (ME) / Radiation Maculopathy / Radiation Retinopathy / Uveal Melanoma1
2TerminatedTreatmentFollicular Lymphoma (FL)1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemias2
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2TerminatedTreatmentMaculopathies, Age-Related / Subfoveal Choroidal Neovascularization1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMantle Cell Lymphoma (MCL)1
2TerminatedTreatmentMultiple Myeloma (MM)11
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2TerminatedTreatmentProphylaxis against postoperative nausea and vomiting / Vomiting1
2TerminatedTreatmentProstate Cancer3
2TerminatedTreatmentRadiculopathy, Cervical1
2TerminatedTreatmentRecurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentRefractory Multiple Myeloma2
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentSurgery, Hand1
2TerminatedTreatmentT-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia1
2Unknown StatusPreventionAirway Obstruction2
2Unknown StatusPreventionProliferative Diabetic Retinopathy (PDR)1
2Unknown StatusPreventionProphylaxis against postoperative nausea and vomiting / Tumors, Solid1
2Unknown StatusSupportive CareNausea / Vomiting1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Unknown StatusTreatmentBortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentDiabetic Macular Edema (DME) / Non-Proliferative Diabetic Retinopathy / Proliferative Diabetic Retinopathy (PDR)1
2Unknown StatusTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentMalignant / Mesothelioma / Pleural1
2Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
2Unknown StatusTreatmentMultiple Myeloma (MM)4
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentPOEMS Syndrome1
2Unknown StatusTreatmentPostoperative pain / Postoperative Vocal Function / Prophylaxis against postoperative nausea and vomiting / Thyroidectomy1
2Unknown StatusTreatmentRectal Carcinoma1
2Unknown StatusTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Unknown StatusTreatmentWaldenström's Macroglobulinemia (WM)1
2WithdrawnPreventionMultiple Myeloma (MM)1
2WithdrawnTreatmentAge Related Macular Degeneration (ARMD)1
2WithdrawnTreatmentAmyloidosis / Immunoglobulin Light Chain Deposition1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentCancer, Breast1
2WithdrawnTreatmentConjunctivitis, Seasonal Allergic1
2WithdrawnTreatmentImmune Thrombocytopenia1
2WithdrawnTreatmentMalignant Lymphomas4
2WithdrawnTreatmentMultiple Myeloma (MM)9
2WithdrawnTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentPatients With Acute Pancreatitis1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentRefractory Plasma Cell Neoplasm / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentRelapse/Refractory Multiple Myeloma2
2WithdrawnTreatmentRenal Cell Adenocarcinoma1
2WithdrawnTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3Active Not RecruitingPreventionAdjuvants, Anesthesia1
2, 3Active Not RecruitingTreatmentImmune Thrombocytopenia / Pregnancy1
2, 3CompletedOtherLocal Anesthesia1
2, 3CompletedPreventionProphylaxis against postoperative nausea and vomiting1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentCellophane Maculopathy / Epiretinal Membrane / Macular Edema (ME) / Retinal Edema1
2, 3CompletedTreatmentMultiple Myeloma (MM)3
2, 3CompletedTreatmentNon-Ischemic Central Retinal Vein Occlusion1
2, 3CompletedTreatmentPemphigus1
2, 3CompletedTreatmentPlantar fascial fibromatosis1
2, 3CompletedTreatmentRetinal Vein Occlusions(RVO)1
2, 3CompletedTreatmentTuberculous Meningitis1
2, 3CompletedTreatmentDiffuse posterior uveitis / Uveitis, Intermediate1
2, 3RecruitingSupportive CareAdvanced Malignant Neoplasm / Cancer Fatigue / Metastatic Malignant Neoplasm / Recurrent Malignant Neoplasm1
2, 3RecruitingSupportive CareOsteoarthritis (OA) / Total Hip Arthroplasty (THA) / Total Knee Arthroplasty (TKA)1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / Leukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, T Cell / Leukemias / Lymphoma, Lymphoblastic1
2, 3RecruitingTreatmentChronic Subdural Hematomas2
2, 3RecruitingTreatmentHepatectomy / Hyperbilirubinemia / Jaundice / Liver Dysfunction1
2, 3RecruitingTreatmentLeukaemia, Lymphoblastic / Leukemia, Acute / Leukemia, T Cell1
2, 3RecruitingTreatmentLeukemias2
2, 3RecruitingTreatmentLymphoma, Lymphoblastic1
2, 3RecruitingTreatmentNeurocysticercosis1
2, 3RecruitingTreatmentPost Surgical Pain1
2, 3RecruitingTreatmentPremature Births1
2, 3RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2, 3TerminatedPreventionShoulder Surgery1
2, 3TerminatedTreatmentAnterior Uveitis (AU)1
2, 3TerminatedTreatmentLeptospirosis1
2, 3TerminatedTreatmentOral Cavity Cancer1
2, 3Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
2, 3Unknown StatusTreatmentLeukemias1
2, 3WithdrawnTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
3Active Not RecruitingBasic ScienceNewly Diagnosed, Previously Untreated Multiple Myeloma1
3Active Not RecruitingPreventionDysphasia1
3Active Not RecruitingPreventionSwallowing Disorders1
3Active Not RecruitingTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)3
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Lymphoblastic Lymphoma / Ann Arbor Stage I B Lymphoblastic Lymphoma / Ann Arbor Stage II B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Hypodiploid B Acute Lymphoblastic Leukemia / Intrachromosomal Amplification of Chromosome 21 / Philadelphia Chromosome Positive / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentBrachial Plexus Block / Postoperative pain1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentGlaucoma1
3Active Not RecruitingTreatmentIdiopathic Thrombocytopenic Purpura (ITP)1
3Active Not RecruitingTreatmentLeukemias3
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLymphoma (Myeloma) / Malignant Lymphomas / Multiple Myeloma (MM)1
3Active Not RecruitingTreatmentMalignant Lymphomas3
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)18
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3Active Not RecruitingTreatmentProstate Cancer1
3Active Not RecruitingTreatmentRefractory Multiple Myeloma / Relapsed Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed and Refractory Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed/Refractory Multiple Myeloma1
3CompletedNot AvailableAcute Otitis Media1
3CompletedNot AvailablePneumonia1
3CompletedDiagnosticDevelopment1
3CompletedDiagnosticPolycystic Ovarian Syndrome1
3CompletedPreventionAcute Urinary Tract Infection / Urinary Tract Infections (UTIs)1
3CompletedPreventionCataracts / Cystoid Macular Edema / Diabetes Mellitus (DM)1
3CompletedPreventionChronic Lung Diseases / Respiratory Distress Syndrome (RDS)1
3CompletedPreventionChronic Renal Failure (CRF)1
3CompletedPreventionDiabetic Macular Edema (DME)1
3CompletedPreventionHernia, Femoral / Inguinal Hernias1
3CompletedPreventionInfection, Postoperative Wound / Surgery, Colon1
3CompletedPreventionNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
3CompletedPreventionNeoplasms1
3CompletedPreventionPelvic Organ Prolapse (POP) / Ponv1
3CompletedPreventionPostoperative Fatigue / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
3CompletedPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
3CompletedPreventionProphylaxis against postoperative nausea and vomiting1
3CompletedPreventionThyroid Diseases / Thyroidectomy1
3CompletedPreventionVomiting1
3CompletedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting11
3CompletedSupportive CareAnemias / Prostate Cancer / Tiredness1
3CompletedSupportive CareBone Metastases1
3CompletedSupportive CareCancers1
3CompletedSupportive CareGenital Neoplasms, Female / Nausea / Vomiting1
3CompletedSupportive CareNausea1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific3
3CompletedSupportive CareNausea and Vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting1
3CompletedSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult T-Cell Leukemia/Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentAcute Otitis Externa2
3CompletedTreatmentAmyloidosis1
3CompletedTreatmentAnaesthesia therapy / Forearm Injuries / Postoperative pain1
3CompletedTreatmentAnterior Uveitis (AU)2
3CompletedTreatmentBlepharoconjunctivitis1
3CompletedTreatmentBone Metastases1
3CompletedTreatmentBronchiolitis1
3CompletedTreatmentCancer of the Ovary1
3CompletedTreatmentCancers / Nausea / Vomiting1
3CompletedTreatmentCarcinoma NOS / Non Small Cell Lung1
3CompletedTreatmentCataracts2
3CompletedTreatmentCataracts / Inflammatory Reaction1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChronic Allergic Conjunctivitis1
3CompletedTreatmentChronic Lung Disease of Prematurity1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentBacterial blepharitis / Conjunctivitis / Corneal Inflammation2
3CompletedTreatmentDiabetic Macular Edema (DME)2
3CompletedTreatmentEffects of Chemotherapy / Multiple Myeloma (MM)1
3CompletedTreatmentEye Dryness1
3CompletedTreatmentFocal Lipoid Glomerulosclerosis / Nephrosis1
3CompletedTreatmentGlomerulosclerosis, Focal Segmental1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Oral Manifestations1
3CompletedTreatmentHeadaches / Intranasal Ketamine1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP)2
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Purpura1
3CompletedTreatmentImmune Thrombocytopenia1
3CompletedTreatmentInfection NOS / Neutropenias1
3CompletedTreatmentInteraction Between Antiemetic Drugs and Paracetamol1
3CompletedTreatmentKnee Injuries1
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemias12
3CompletedTreatmentLeukemias / Malignant Lymphomas2
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentLung Cancers / Metastatic Cancers1
3CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentM-Protein / Multiple Myeloma (MM) / Myeloma Proteins / Plasma Cell Myeloma1
3CompletedTreatmentMacular Edema (ME)1
3CompletedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)2
3CompletedTreatmentMacular Edema (ME) / Uveitis1
3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentMigraines2
3CompletedTreatmentMultiple Myeloma (MM)26
3CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm6
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Renal Failure1
3CompletedTreatmentMultiple Myeloma de Novo Treatment1
3CompletedTreatmentNausea / Prophylaxis of acute chemotherapy induced nausea and vomiting / Vomiting1
3CompletedTreatmentNeurocysticercosis1
3CompletedTreatmentNonneoplastic Condition1
3CompletedTreatmentOcular Inflammation Associated With Blepharaconjunctivitis1
3CompletedTreatmentPain Management After Surgery1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentPost Ocular Surgical Inflammation and Pain2
3CompletedTreatmentPost Ocular Surgical Inflammation and Pain / Post-Surgical Ocular Inflammation / Post-Surgical Ocular Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentPrimary Systemic Amyloidosis (AL)1
3CompletedTreatmentProstate Cancer2
3CompletedTreatmentPurpura, Thrombocytopenic, Idiopathic1
3CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
3CompletedTreatmentRelapsed/Refractory Multiple Myeloma1
3CompletedTreatmentRespiratory Distress Syndrome (RDS)1
3CompletedTreatmentRotator Cuff Syndrome / Shoulder Bursitis1
3CompletedTreatmentUpper Extremity Fractures1
3CompletedTreatmentBacterial blepharitis2
3CompletedTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting2
3Enrolling by InvitationTreatmentHip Disease1
3Not Yet RecruitingPreventionCesarean Section Complications1
3Not Yet RecruitingPreventionOvarian Hyperstimulation Syndrome1
3Not Yet RecruitingPreventionHypersensitivity reactions1
3Not Yet RecruitingSupportive CareColorectal Cancers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
3Not Yet RecruitingSupportive CareNeoplasms, Malignant1
3Not Yet RecruitingSupportive CarePostoperative pain1
3Not Yet RecruitingSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting1
3Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphocytic Leukemia (ALL) / Leukaemia, Lymphoblastic / Leukemia, Lymphoblastic, Acute, Philadelphia-Positive / Lymphoblastic Leukemia, Acute, Adult / Ph1 Chromosome1
3Not Yet RecruitingTreatmentBronchiolitis1
3Not Yet RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3Not Yet RecruitingTreatmentHSV Encephalitis1
3Not Yet RecruitingTreatmentIV Drug Usage1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic1
3Not Yet RecruitingTreatmentMultiple Myeloma (MM)2
3Not Yet RecruitingTreatmentObstetric Pain / Other Complications of Obstetric Anesthesia - Delivered1
3RecruitingOtherAsthma Bronchial1
3RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3RecruitingPreventionChildhood Cancers / Nausea / Vomiting1
3RecruitingPreventionPain1
3RecruitingPreventionProphylaxis of acute chemotherapy induced nausea and vomiting2
3RecruitingSupportive CareBrachial Plexus Block1
3RecruitingSupportive CareCarcinoma, Breast1
3RecruitingSupportive CareMalignant Neoplasms of Independent (Primary) Multiple Sites1
3RecruitingSupportive CareMalignant Neoplasms of Male Genital Organs1
3RecruitingSupportive CareProphylaxis of acute chemotherapy induced nausea and vomiting1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAcute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3RecruitingTreatmentAmyloidosis1
3RecruitingTreatmentAnesthesia, Conduction1
3RecruitingTreatmentAsthma Bronchial2
3RecruitingTreatmentB Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
3RecruitingTreatmentCancer - Small Cell Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentCardiopulmonary Bypass / Defect, Congenital Heart / Surgery, Cardiac1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3RecruitingTreatmentCochlear Implants / Sensorineural Hearing Loss1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3RecruitingTreatmentAcute nonspecific tenosynovitis / DeQuervain's Tenosynovitis / Inflammatory Diseases / Lateral Epicondylitis / Trigger Finger1
3RecruitingTreatmentDrug-Induced Liver Injury / Human Immunodeficiency Virus (HIV) / IRIS / Tuberculosis / Tuberculous Meningitis1
3RecruitingTreatmentDrug-Induced Liver Injury / Tuberculosis / Tuberculous Meningitis1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal Type1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type1
3RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
3RecruitingTreatmentForearm Fractures / Forearm Wound / Hand Fractures / Hand Wound / Surgery of Forearm / Surgery of Hand / Surgery of Wrist / Wrist Fractures / Wrist Wound1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentInflammatory Macular Edema1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
3RecruitingTreatmentMacular Edema (ME)1
3RecruitingTreatmentMacular Edema (ME) / Uveitis1
3RecruitingTreatmentMajor Non-cardiac Surgery1
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingTreatmentMultiple Myeloma (MM)15
3RecruitingTreatmentNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type / Non-Hodgkin T-cell Lymphoma / Non-Hodgkin's Lymphoma, Relapsed1
3RecruitingTreatmentNeuroblastomas / Opsoclonus Myoclonus Syndrome1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentPain1
3RecruitingTreatmentPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentPlasma Cell Myeloma2
3RecruitingTreatmentPlasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3RecruitingTreatmentPlasmacytoma1
3RecruitingTreatmentPostoperative pain1
3RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
3RecruitingTreatmentPurpura, Thrombocytopenic, Idiopathic1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSoft Tissue Sarcoma (STS)1
3RecruitingTreatmentSolitary Osseous Plasmacytoma1
3RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
3TerminatedSupportive CareHeadaches / Vomiting1
3TerminatedTreatmentAcute Fungal Otitis Externa1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentAcute Otitis Externa1
3TerminatedTreatmentChronic Lung Disease of Prematurity / Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Respiratory Distress Syndrome (RDS)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentDysphagia After Anterior Cervical Decompression and Fusion of the Spine1
3TerminatedTreatmentLiver Cirrhosis1
3TerminatedTreatmentMalignant Lymphomas2
3TerminatedTreatmentMultiple Myeloma (MM)5
3TerminatedTreatmentOtitis Externa1
3TerminatedTreatmentOtitis Media in Patients With Tympanostomy Tubes1
3TerminatedTreatmentProstate Cancer1
3TerminatedTreatmentSickle Cell Disorders1
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3TerminatedTreatmentVomiting2
3Unknown StatusPreventionDrug hypersensitivity reaction1
3Unknown StatusPreventionNausea / Vomiting1
3Unknown StatusPreventionRespiratory; Disorder, Functional, Impaired1
3Unknown StatusTreatmentAcute Bacterial Conjunctivitis1
3Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Unknown StatusTreatmentAcute Otitis Externa1
3Unknown StatusTreatmentAcute / Conjunctivitis, Bacterial1
3Unknown StatusTreatmentAllergies / Skin Inflammation1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Fungal Vaginal Infections1
3Unknown StatusTreatmentExtramedullary Plasmacytoma1
3Unknown StatusTreatmentHELLP Syndrome1
3Unknown StatusTreatmentLeukemias2
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)1
3Unknown StatusTreatmentMalignant Lymphomas7
3Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
3Unknown StatusTreatmentMultiple Myeloma (MM)4
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3Unknown StatusTreatmentNonneoplastic Condition1
3Unknown StatusTreatmentOral Lichen Planus1
3Unknown StatusTreatmentPost-Operative Pain1
3Unknown StatusTreatmentSarcoidosis1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3Unknown StatusTreatmentNeurocostal neuralgia1
3WithdrawnSupportive CareCancers / Nausea and Vomiting / Prophylaxis of acute chemotherapy induced nausea and vomiting / Solid Tumor Cancers1
3WithdrawnTreatmentBlepharoconjunctivitis1
3WithdrawnTreatmentDisorder of Rotator Cuff / Disorder of Shoulder / Disorder of Tendon of Biceps / Injury of Shoulder Region / Shoulder Pain1
3WithdrawnTreatmentIdiopathic Thrombocytopenic Purpura (ITP) / Purpura2
3WithdrawnTreatmentMultiple Myeloma (MM)1
3WithdrawnTreatmentPost-surgical Inflammation1
3WithdrawnTreatmentSkin Inflammation1
4Active Not RecruitingPreventionPostoperative Cognitive Dysfunction1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4Active Not RecruitingTreatmentAmbulatory Surgical Procedures / Brachial Plexus Block / Postoperative pain / Shoulder Joint Disorder1
4Active Not RecruitingTreatmentDiabetic Macular Edema (DME)1
4Active Not RecruitingTreatmentHELLP Syndrome1
4Active Not RecruitingTreatmentInflammation Eye1
4Active Not RecruitingTreatmentMedical Induction of Labor Affecting Fetus1
4Active Not RecruitingTreatmentModified Radical Mastectomy1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)2
4Active Not RecruitingTreatmentOpen-angle Glaucoma (OAG)1
4Active Not RecruitingTreatmentVomiting2
4CompletedNot AvailablePostoperative pain1
4CompletedBasic ScienceCancer of the Ovary1
4CompletedBasic SciencePremature Births1
4CompletedDiagnosticConjunctivitis, Seasonal Allergic1
4CompletedHealth Services ResearchBronchiolitis1
4CompletedOtherPain / Shoulder Arthroscopy1
4CompletedPreventionAcute Leukemic Patients in Children1
4CompletedPreventionArthrosis, Unspecified, Ankle and Foot1
4CompletedPreventionChronic Obstructive Pulmonary Disease (COPD)2
4CompletedPreventionCisplatin Ototoxicity1
4CompletedPreventionEdema1
4CompletedPreventionFoot and Ankle Procedures1
4CompletedPreventionFractures, Bone / Morphine Adverse Reaction / Nausea and Vomiting, Postoperative / Pruritus / Satisfaction, Personal1
4CompletedPreventionKeloid Scars1
4CompletedPreventionMigraines2
4CompletedPreventionNausea / Neoplasms / Vomiting1
4CompletedPreventionNausea / Postoperative Nausea and Vomiting (PONV)1
4CompletedPreventionNausea / Vomiting1
4CompletedPreventionPain Measurement1
4CompletedPreventionPain / Throat Pain1
4CompletedPreventionPostoperative Cognitive Dysfunction1
4CompletedPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting8
4CompletedPreventionThroat Pain1
4CompletedPreventionVomiting1
4CompletedSupportive CareCancers / Tumors1
4CompletedSupportive CareFracture, Ankle1
4CompletedSupportive CareInterscalene Blockade in Elective Arthroscopic Rotator Cuff Repair / Shoulder Injury1
4CompletedSupportive CarePonv1
4CompletedSupportive CarePostoperative pain1
4CompletedTreatmentAbdominal Surgeries / Analgesia, Patient-Controlled / Analgesia, Postoperative / Postoperative pain1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
4CompletedTreatmentAnaesthetics Gases, Xenon / Anaesthetics Volatile, Sevoflurane / Depth of Anaesthesia / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentAnterior Cruciate Ligament Reconstruction / Regional Anesthesia, Saphenous Nerve Block1
4CompletedTreatmentArthritis / Shoulder Impingement Syndrome1
4CompletedTreatmentAsthma Bronchial / Reactive Airways Disease (RAD)1
4CompletedTreatmentAtypical Facial Pain / Typical Facial Pain1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCancer, Breast / Dexamethasone / Glucocorticoid therapy / Mastectomy / Nausea and Vomiting, Postoperative / Postoperative Complications / Postoperative pain / Steroid / Systemic Inflammatory Response Syndrome (SIRS)1
4CompletedTreatmentCataracts / Cystoid Macular Edema Following Cataract Surgery / Diabetic Macular Edema (DME) / Macular Edema, Cystoid / Vision Disorders1
4CompletedTreatmentCroup1
4CompletedTreatmentDiabetic Macular Edema (DME)2
4CompletedTreatmentDiabetic Macular Edema (DME) / Epiretinal Membrane1
4CompletedTreatmentDisorder of Shoulder / Postoperative pain1
4CompletedTreatmentEpithelial Defect After Phototherapeutic Keratectomy1
4CompletedTreatmentIncomplete Reversal of Neuromuscular Block1
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentIntraocular Pressure1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)2
4CompletedTreatmentLocal Anesthesia1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMacular Edema (ME) / Retinal Vein Occlusions(RVO)2
4CompletedTreatmentMacular Edema (ME) / Uveitis1
4CompletedTreatmentMultiple Myeloma (MM)1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentNasal Surgery1
4CompletedTreatmentNausea / Vomiting2
4CompletedTreatmentNonvalvular Atrial Fibrillation / Surgery, Cardiac1
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedTreatmentOsteoarthritis (OA)1
4CompletedTreatmentOsteoarthritis, Hip1
4CompletedTreatmentPTSD1
4CompletedTreatmentPain1
4CompletedTreatmentPain, Acute / Pain, Chronic1
4CompletedTreatmentPain / Peripheral Nerve Blocks1
4CompletedTreatmentPain / Postoperative1
4CompletedTreatmentPain / Shoulder Arthroscopy1
4CompletedTreatmentPeripheral Arterial Disease (PAD)1
4CompletedTreatmentPostoperative Complications1
4CompletedTreatmentPostoperative Sore Throat, Cough, Hoarseness1
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPurpura, Thrombocytopenic, Idiopathic1
4CompletedTreatmentRecession, Gingival1
4CompletedTreatmentRetinal Vein Occlusions(RVO)1
4CompletedTreatmentRupture of Anterior Cruciate Ligament1
4CompletedTreatmentSjögren's Syndrome1
4CompletedTreatmentTotal Knee Arthroplasty (TKA)1
4CompletedTreatmentVernal Keratoconjunctivitis1
4CompletedTreatmentViral Bronchiolitis1
4Enrolling by InvitationTreatmentSacro-Iliac Spondylosis1
4Not Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingTreatmentAddison's Disease1
4Not Yet RecruitingTreatmentArthroplasty, Knee Replacement / Postoperative pain1
4Not Yet RecruitingTreatmentCancers / Nausea / Vomiting1
4Not Yet RecruitingTreatmentCorneal Endothelial Cell Loss / Corneal Endothelial Decompensation / Dexamethasone Adverse Reaction / Diabetes Mellitus (DM)1
4Not Yet RecruitingTreatmentDiabetic Macular Edema (DME)1
4Not Yet RecruitingTreatmentInflammatory Responses1
4Not Yet RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
4Not Yet RecruitingTreatmentOtitis Media (OM) / Otorrhoea1
4Not Yet RecruitingTreatmentOtitis Media With Effusion in Children / Otorrhoea1
4Not Yet RecruitingTreatmentPostoperative pain2
4Not Yet RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingTreatmentRadiculopathy, Cervical2
4Not Yet RecruitingTreatmentTuberculous Meningitis1
4Not Yet RecruitingTreatmentPh+ Acute Lymphoblastic Leukemia1
4RecruitingNot AvailableLung Cancers1
4RecruitingBasic ScienceCritical Limb Ischemia (CLI) / Peripheral Artery Disease (PAD) / Vascular Diseases1
4RecruitingBasic ScienceInsulin Secretion1
4RecruitingOtherHand Injury Wrist / Peripheral Nerve Block Prolongation1
4RecruitingPreventionAnesthesia, Pediatrics, Surgery1
4RecruitingPreventionDelirium / Dexamethasone / Flubiprofen Axetil / Lung Cancer Non-Small Cell Cancer (NSCLC) / Surgery--Complications1
4RecruitingPreventionDelirium / Postoperative Cognitive Dysfunction1
4RecruitingPreventionHyaline Membrane Disease / Necrotizing Enterocolitis of Newborn1
4RecruitingPreventionLaparoscopic Sleeve Gastrectomy / Prophylaxis against postoperative nausea and vomiting1
4RecruitingPreventionNeuritis / Radioiodine ablation of thyroid tissue1
4RecruitingPreventionPostoperative Complications1
4RecruitingPreventionPostoperative pain1
4RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
4RecruitingSupportive CareDexamethasone / Flubiprofen Axetil / General Surgery / Long-Term Effects Secondary to Cancer Therapy in Adults / Lung Cancer Non-Small Cell Cancer (NSCLC)1
4RecruitingSupportive CareObstructive Sleep Apnea (OSA)1
4RecruitingSupportive CareTonsillitis1
4RecruitingTreatmentAbdominal Pain (AP) / Nausea1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)3
4RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)1
4RecruitingTreatmentAnterior Cruciate Ligament Injury1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentCancers1
4RecruitingTreatmentCentral Retinal Vein Occlusion (CRVO) / Macular Edema (ME)1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified1
4RecruitingTreatmentChronic Pain Post-Proceduraal / Nausea and Vomiting, Postoperative / Postoperative pain1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentDexamethasone Effect on Induction of Labor1
4RecruitingTreatmentDexamethasone / Supraclavicular Brachial Plexus Block1
4RecruitingTreatmentDiabetes Mellitus (DM) / Macular Edema (ME) / Retinal Exudates and Deposits1
4RecruitingTreatmentDiabetic Macular Edema (DME)1
4RecruitingTreatmentEarly-Stage Breast Cancer / Pain Syndrome1
4RecruitingTreatmentHeadaches1
4RecruitingTreatmentImmune Thrombocytopenia1
4RecruitingTreatmentInflammatory Reaction / Intraocular Pressure1
4RecruitingTreatmentInflammatory Reaction / Osteoarthritis (OA) / Postoperative pain1
4RecruitingTreatmentKidney Diseases / Postoperative Complications1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentLocalized Primary Osteoarthritis of Both Hips (Diagnosis) / Osteoarthritis, Hip1
4RecruitingTreatmentLower Limb Injury / Postoperative pain1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentMultiple Myeloma (MM)1
4RecruitingTreatmentMyofascial Pain Syndrome1
4RecruitingTreatmentPain, Acute1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPain, Radiating1
4RecruitingTreatmentPediatric Post-tonsillectomy Pain1
4RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentCaudal epidural block therapy / Postoperative pain1
4RecruitingTreatmentProphylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
4RecruitingTreatmentCaudal epidural block therapy / Shoulder Surgery1
4TerminatedPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4TerminatedTreatmentAsthma Bronchial / Status Asthmaticus / Wheezing1
4TerminatedTreatmentGeneral Surgery1
4TerminatedTreatmentHematoma, Subdural, Chronic1
4TerminatedTreatmentHip Fractures1
4TerminatedTreatmentPain1
4TerminatedTreatmentPostoperative pain2
4TerminatedTreatmentTrigger Finger Disorder1
4TerminatedTreatmentTumors1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentArthritis1
4Unknown StatusTreatmentChronic Rhinosinusitis1
4Unknown StatusTreatmentDexamethasone / Interscalene Block / Low Volume Regional Anesthesia / Shoulder Arthroscopy1
4Unknown StatusTreatmentDuration of Pain Relief1
4Unknown StatusTreatmentFracture of Neck of Femur1
4Unknown StatusTreatmentInfertilities1
4Unknown StatusTreatmentPost Minimally Invasive Thorascopic Surgical Pain1
4Unknown StatusTreatmentPostoperative pain1
4WithdrawnNot AvailableAdrenal Insufficiency1
4WithdrawnSupportive CareRetinal Detachment1
4WithdrawnTreatmentAnalgesia Duration1
4WithdrawnTreatmentBronchiolitis Acute1
4WithdrawnTreatmentImmune Thrombocytopenia1
4WithdrawnTreatmentNeuromuscular Blockade1
4WithdrawnTreatmentPain / Total Knee Arthroplasty (TKA)1
4WithdrawnTreatmentPost Operative Pain Control1
Not AvailableActive Not RecruitingNot AvailableDiabetic Macular Edema (DME)1
Not AvailableActive Not RecruitingPreventionSwallowing Disorders1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentCervical Spine1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableApproved for MarketingNot AvailableMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)2
Not AvailableAvailableNot AvailableMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
Not AvailableCompletedNot AvailableAdenotonsillectomy / Tonsillectomy1
Not AvailableCompletedNot AvailableAmyloidosis1
Not AvailableCompletedNot AvailableDiabetic Macular Edema (DME)1
Not AvailableCompletedNot AvailableGlucose tolerance impaired / Insulin Resistance1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableMacular Edema (ME)3
Not AvailableCompletedNot AvailableMacular Edema (ME) / Retinal Vein Occlusions(RVO)3
Not AvailableCompletedNot AvailableDiffuse posterior uveitis / Macular Edema (ME) / Retinal Vein Occlusions(RVO)1
Not AvailableCompletedNot AvailableMacular Edema (ME) / Visual Acuity1
Not AvailableCompletedNot AvailableMacular Oedema / Retinal Vein Occlusions(RVO)1
Not AvailableCompletedNot AvailableMultiple Myeloma (MM)1
Not AvailableCompletedNot AvailableNeuromuscular Blockade1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailablePost-operative Swallowing Disorders / Thyroidectomy1
Not AvailableCompletedNot AvailableRetinal Vein Occlusions(RVO)1
Not AvailableCompletedBasic ScienceAnterior Uveitis (AU) / Iridocyclitis / Iritis / Macular Edema (ME) / Uveitis1
Not AvailableCompletedBasic ScienceExperimental Lung Inflammation1
Not AvailableCompletedBasic SciencePTSD1
Not AvailableCompletedBasic SciencePosttraumatic Stress Disorders1
Not AvailableCompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableCompletedOtherLumbosacral Radicular Pain1
Not AvailableCompletedOtherProlonged Motor Block / Prolonged Sensory Block / Spinal Anaesthesia1
Not AvailableCompletedPreventionBlood Diseases / Graft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT) / Leukemias / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Transplantation, Bone Marrow1
Not AvailableCompletedPreventionCesarean Section / Pruritus1
Not AvailableCompletedPreventionEndometriosis of Uterus / Uterine Leiomyomas1
Not AvailableCompletedPreventionGynecological Disease1
Not AvailableCompletedPreventionInflammation Following Cataract Surgery1
Not AvailableCompletedPreventionInflammatory Reaction1
Not AvailableCompletedPreventionPost Lasik Surgery Inflammation1
Not AvailableCompletedPreventionPost Operative Sore Throat1
Not AvailableCompletedPreventionPrevention of Hypersensitivity Reactions to Paclitaxel1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting8
Not AvailableCompletedPreventionTransient Tachypnea of the Newborn1
Not AvailableCompletedPreventionWound Infections1
Not AvailableCompletedScreeningPolycystic Ovaries Syndrome1
Not AvailableCompletedSupportive CareCancer of the Ovary / Cancer, Breast / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Nausea and Vomiting / Neuroblastomas / Testicular germ cell tumour1
Not AvailableCompletedSupportive CareCancers1
Not AvailableCompletedSupportive CareInfertilities1
Not AvailableCompletedSupportive CareLower Extremities Fracture1
Not AvailableCompletedSupportive CareMale Breast Cancer / Nausea and Vomiting / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedSupportive CareNeoplasms, Malignant1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedSupportive CarePain / Recurrent Oropharyngeal Squamous Cell Carcinoma / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Swallowing Disorders1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Effects of Chemotherapy / Prophylaxis of acute chemotherapy induced nausea and vomiting / Sarcomas1
Not AvailableCompletedTreatmentAmyloidosis / Leukemias1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnal Condyloma / Fissure in Ano / Hemorrhoids / Rectal Fistulas1
Not AvailableCompletedTreatmentAnalgesia, Postoperative1
Not AvailableCompletedTreatmentAnalgesia / Postoperative pain1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentAsthma Bronchial / Reactive Airways Disease (RAD)1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBack Pain / Cervical Pain1
Not AvailableCompletedTreatmentCardiac Diseases / Postoperative Complications / Systemic Inflammatory Response Syndrome (SIRS)1
Not AvailableCompletedTreatmentCataracts1
Not AvailableCompletedTreatmentCentral Retinal Vein Occlusion (CRVO) / Macular Edema (ME)1
Not AvailableCompletedTreatmentChalazion Both Eyes / Chalazion Left Eye, Unspecified Eyelid / Chalazion Right Eye, Unspecified Eyelid / Chalazion Unspecified Eye, Unspecified Eyelid1
Not AvailableCompletedTreatmentClinically Significant Macular Edema / Diabetic Macular Edema (DME) / Macular Edema, Cystoid / Vision Disorders1
Not AvailableCompletedTreatmentCorneal Diseases1
Not AvailableCompletedTreatmentCysticercosis / Epilepsies1
Not AvailableCompletedTreatmentDiabetic Macular Edema (DME) / Vision Disorders1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentEdema / Pain / Trismus2
Not AvailableCompletedTreatmentGeneral Surgery1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentImpaired Fasting Glucose (IFG) / Impaired Glucose Tolerance (IGT) / Pre-Diabetic1
Not AvailableCompletedTreatmentIntraventricular Hemorrhage / Neonatal Mortality / Respiratory Distress Syndrome (RDS)1
Not AvailableCompletedTreatmentLateral Elbow Pain1
Not AvailableCompletedTreatmentLeukemias3
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentNeoplasms, Pancreatic1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentParathyroid Diseases / Thyroid Diseases1
Not AvailableCompletedTreatmentPituitary Adenomas / Pituitary Diseases1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentPost Surgical Pain1
Not AvailableCompletedTreatmentPost-operative Hemorrhage1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentPostoperative pain / Prophylaxis against postoperative nausea and vomiting / Tiredness1
Not AvailableCompletedTreatmentPosttraumatic Stress Disorders1
Not AvailableCompletedTreatmentPreterm Premature Rupture of Membranes1
Not AvailableCompletedTreatmentProphylaxis against postoperative nausea and vomiting2
Not AvailableCompletedTreatmentProstate Ca1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentViral Bronchiolitis1
Not AvailableEnrolling by InvitationTreatmentGeneral Surgery / Molar, Third1
Not AvailableNot Yet RecruitingOtherUpper Extremity Injury1
Not AvailableNot Yet RecruitingPreventionNausea and Vomiting1
Not AvailableNot Yet RecruitingPreventionPostoperative pain / Ureter Stone1
Not AvailableNot Yet RecruitingTreatmentBell's Palsy1
Not AvailableNot Yet RecruitingTreatmentCapsular Contracture, Implant1
Not AvailableNot Yet RecruitingTreatmentInfertility, Female1
Not AvailableNot Yet RecruitingTreatmentLow Back Pain (LBP)1
Not AvailableNot Yet RecruitingTreatmentOphthalmology1
Not AvailableNot Yet RecruitingTreatmentPain, Acute / Postoperative pain / Upper Extremity Injury1
Not AvailableNot Yet RecruitingTreatmentProphylaxis of acute chemotherapy induced nausea and vomiting1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableDiabetic Macular Edema (DME)1
Not AvailableRecruitingNot AvailableMultiple Myeloma (MM)2
Not AvailableRecruitingNot AvailableNon-Infectious Uveitis1
Not AvailableRecruitingNot AvailableRelapsed and/or Refractory Multiple Myeloma1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenemia / Polycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Hyperandrogenism / Polycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceFibrosis of the Retina / Macular Edema (ME)1
Not AvailableRecruitingDiagnosticRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableRecruitingPreventionBilateral Superficial Cervical Block1
Not AvailableRecruitingPreventionCytokines / Dexamethasone / Pain, Chronic / Thoracic Surgery1
Not AvailableRecruitingPreventionNeonatal Respiratory Distress Syndrome1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingPreventionProphylaxis of acute chemotherapy induced nausea and vomiting1
Not AvailableRecruitingSupportive CareCancer, Breast / Prophylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareColonic Neoplasms1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukemia Ph Positive1
Not AvailableRecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentAge-related Cataract1
Not AvailableRecruitingTreatmentAllergies / Urticarias1
Not AvailableRecruitingTreatmentAmyloidosis; Systemic1
Not AvailableRecruitingTreatmentApnea, Obstructive / Hard of Hearing / Nasal Obstruction / Nasopharyngeal Obstruction / Otitis / Snoring1
Not AvailableRecruitingTreatmentCataracts1
Not AvailableRecruitingTreatmentChildhood Acute Lymphoblastic Leukemia1
Not AvailableRecruitingTreatmentDental Research / Pharmaceutical Preparations, Dental1
Not AvailableRecruitingTreatmentEpiretinal Membrane / Macular Edema (ME)1
Not AvailableRecruitingTreatmentEpiretinal Membrane / Macular Edema (ME) / Vitrectomy therapy1
Not AvailableRecruitingTreatmentImpacted Third Molar Tooth1
Not AvailableRecruitingTreatmentLigament Injury / Nerve Entrapment / Osteoarthritis (OA) / Rheumatoid Arthritis1
Not AvailableRecruitingTreatmentMyopia / Refractive Errors1
Not AvailableRecruitingTreatmentPelvic Organ Prolapse (POP) / Prolapses, Vaginal Vault / Quality of Life1
Not AvailableRecruitingTreatmentPostoperative pain1
Not AvailableRecruitingTreatmentRupture of Anterior Cruciate Ligament / Tear of Anterior Cruciate Ligament1
Not AvailableRecruitingTreatmentStiffness Following Total Knee Arthroplasty1
Not AvailableRecruitingTreatmentVideo-assisted Thoracic Surgery (VATS) / Video-assisted Thoracoscopic Surgery (VATS)1
Not AvailableRecruitingTreatmentCaudal epidural block therapy1
Not AvailableTerminatedOtherLumbar Back Pain / Lumbar Radiculitis / Lumbar Spine Disc Herniation1
Not AvailableTerminatedSupportive CareMalignant Digestive System Neoplasm / Nausea and Vomiting1
Not AvailableTerminatedSupportive CareMalignant Ovarian Mixed Epithelial Tumor / Nausea and Vomiting / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Stage II Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
Not AvailableTerminatedSupportive CarePain1
Not AvailableTerminatedTreatmentCellulitis1
Not AvailableTerminatedTreatmentEclampsia1
Not AvailableTerminatedTreatmentEpiretinal Membrane / Macular Edema (ME)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentInflammatory Bowel Diseases (IBD)1
Not AvailableTerminatedTreatmentInflammatory Reaction / Perioperative Morbidity1
Not AvailableTerminatedTreatmentLaparoscopic Colorectal Resection1
Not AvailableTerminatedTreatmentLymphohistiocytosis, Hemophagocytic1
Not AvailableTerminatedTreatmentTotal Knee Arthroplasty (TKA)1
Not AvailableUnknown StatusPreventionAsymptomatic Gallstones Without Cholecystitis / Gallbladder Polyps1
Not AvailableUnknown StatusPreventionNausea / Vomiting1
Not AvailableUnknown StatusPreventionPharyngitis1
Not AvailableUnknown StatusPreventionPonv / Pregnancy1
Not AvailableUnknown StatusPreventionRespiratory Sounds1
Not AvailableUnknown StatusSupportive CareBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Radiation Toxicity1
Not AvailableUnknown StatusTreatmentAnalgesia1
Not AvailableUnknown StatusTreatmentEarly Gastric Cancer or Gastric Adenoma1
Not AvailableUnknown StatusTreatmentEdema / Pain / Trismus1
Not AvailableUnknown StatusTreatmentFull-frequency Sudden Hearing Loss1
Not AvailableUnknown StatusTreatmentGlaucoma1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentRadicular Pain1
Not AvailableUnknown StatusTreatmentRadiculopathy, Cervical1
Not AvailableUnknown StatusTreatmentStridor1
Not AvailableWithdrawnNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableWithdrawnBasic ScienceCoronary Artery Bypass Graft Surgery / Coronary Artery Stenosis1
Not AvailableWithdrawnPreventionRespiratory Complications / Swallowing Disorders1
Not AvailableWithdrawnSupportive CareNeoplasms, Malignant / Ototoxicity1
Not AvailableWithdrawnTreatmentDescemet's Stripping Endothelial Keratoplasty / Endothelial Dystrophy / Posterior Lamellar Keratoplasty / Secondary Bullous Keratopathy1
Not AvailableWithdrawnTreatmentDiabetic Macular Edema (DME)1
Not AvailableWithdrawnTreatmentGlioblastoma Multiforme (GBM)1
Not AvailableWithdrawnTreatmentInsulin-dependent Diabetics / Shoulder Injury1
Not AvailableWithdrawnTreatmentPain, Sciatic Block1
Not AvailableWithdrawnTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • Amend
  • American Regent
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bausch & Lomb Inc.
  • Baxter International Inc.
  • Bimeda Inc.
  • Blansett Pharmacal Co. Inc.
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Clint Pharmaceutical Inc.
  • Consolidated Midland Corp.
  • Darby Dental Supply Co. Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • ECR Pharmaceuticals
  • Falcon Pharmaceuticals Ltd.
  • General Injectables and Vaccines Inc.
  • Generics Puerto Rico Inc.
  • Keene Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Luitpold Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Martica Enterprises Inc.
  • Martin Surgical Supply
  • Medisca Inc.
  • Merck & Co.
  • Merit Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • MWI Veterinary Supply Co.
  • National Pharmaceuticals
  • Neuman Distributors Inc.
  • Nord Ost Corp.
  • Nucare Pharmaceuticals Inc.
  • Ocusoft
  • Paddock Labs
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Primedics Laboratories
  • Qualitest
  • Raz Co. Inc.
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Robar Inc.
  • Roxane Labs
  • San Jose Surgical Supply Inc.
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Strides Arcolab Limited
  • Teva Pharmaceutical Industries Ltd.
  • Veratex Corp.
  • Wa Butler Co.
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
OintmentTopical
ImplantIntracardiac.7 mg
SuspensionAuricular (otic)
Suspension / dropsAuricular (otic)
LiquidDental
Kit
LiquidAuricular (otic); Ophthalmic1 mg
TabletOral.5 mg
Injection, solutionOphthalmic
Injection, solutionIntraocular
ElixirOral.5 mg/5mL
SolutionOral.5 mg/5mL
TabletOral.5 mg/1
TabletOral.75 mg/1
TabletOral1 mg/1
TabletOral1.5 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral6 mg/1
Solution, concentrateOral1 mg/mL
LiquidIntramuscular; Intrasynovial; Intravenous10 mg
InjectionIntra-articular; Intralesional; Intramuscular; Intravenous4 mg/5mL
InjectionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg/mL
InjectionIntramuscular10 mg/mL
InjectionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg/mL
Injection, solutionIntramuscular4 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/mL
Injection, solutionIntravenous4 mg/mL
SolutionOphthalmic1 mg/mL
Solution / dropsOphthalmic1 mg/mL
SolutionIntramuscular; Intrasynovial; Intravenous4 mg
SolutionIntramuscular; Intrasynovial; Intravenous10 mg
LiquidIntra-articular; Intramuscular; Intravenous4 mg
SolutionIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg
SolutionIntramuscular; Intravenous10 mg
LiquidIntra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue4 mg
Kit
Injection, suspensionIntraocular517 ug/.005mL
ImplantIntracardiac.5 mg
ImplantIntracardiac0.5 mg
LiquidIntramuscular; Intravenous4 mg
KitIntramuscular; Intravenous; Topical
OintmentOphthalmic0.1 %
SuspensionOphthalmic0.1 %
SuspensionOphthalmic1 mg/mL
Solution / dropsOphthalmic
LiquidAuricular (otic); Ophthalmic
TabletOral40 mg
OintmentOphthalmic
SuspensionOphthalmic
Suspension / dropsOphthalmic
LiquidOphthalmic; Topical.1 %
SolutionAuricular (otic); Ophthalmic0.1 %
ImplantIntravitreal.7 mg/1
ImplantIntravitreal0.7 mg
ImplantIntravitreal700 mcg
ElixirOral0.5 mg
LiquidOral0.5 mg
TabletOral0.5 mg
TabletOral0.75 mg
TabletOral4 mg
TabletOral2 mg
LiquidIntramuscular; Intravenous10 mg
SolutionIntra-articular; Intramuscular; Intravenous4 mg
Solution / dropsAuricular (otic); Ophthalmic.1 %
KitEpidural; Infiltration; Intramuscular; Intravenous
Solution / dropsAuricular (otic); Ophthalmic0.1 %
SolutionAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic); Ophthalmic
Solution / dropsTopical
OintmentAuricular (otic); Ophthalmic
Prices
Unit descriptionCostUnit
Ozurdex 0.7 mg implant1554.0USD implant
Maxidex 0.1% Suspension 15ml Bottle97.96USD bottle
Maxitrol 0.1-5-10000 Ointment 3.5 gm Tube87.3USD tube
Maxitrol 5-10000-0.1 Suspension 5ml Bottle75.88USD bottle
Maxidex 0.1% Suspension 5ml Bottle53.57USD bottle
Dexamethasone Sodium Phosphate 4 mg/ml Solution (1 Box = 25x1ml Vials)41.99USD box
Dexamethasone micronized powd41.31USD g
Dexamethasone powder21.27USD g
Dexamethasone Sodium Phosphate 0.1% Solution 5ml Bottle19.99USD bottle
Dexamethasone acetate powd15.12USD g
Dexamethasone sod ph powder14.24USD g
Dexamethasone Sodium Phosphate 4 mg/ml Solution 5ml Vial13.99USD vial
Dexamethasone Sodium Phosphate 10 mg/ml4.78USD ml
Dexamethasone Sodium Phosphate 4 mg/ml 1 Vial = 5ml4.0USD ml
Dexamethasone 0.1% eye drop3.43USD ml
Dexasol 0.1% eye drops3.38USD ml
Maxidex 0.1 % Ointment2.69USD g
Dexamethasone 10 mg/ml vial2.56USD ml
Maxidex 0.1% eye drops2.36USD ml
Dexamethasone Sodium Phosphate 4 mg/ml1.77USD ml
Maxidex 0.1 % Suspension1.73USD ml
Sandoz Dexamethasone Sod. Phosphate 0.1 % Solution1.38USD ml
Pms-Dexamethasone Sodium Phosp 10 mg/ml1.34USD ml
Dexamethasone 4 mg/ml vial1.04USD ml
Dexamethasone 6 mg tablet1.01USD tablet
Dexasone 4 mg Tablet0.86USD tablet
Apo-Dexamethasone 4 mg Tablet0.8USD tablet
Pms-Dexamethasone 4 mg Tablet0.8USD tablet
Ratio-Dexamethasone 4 mg Tablet0.8USD tablet
Dexamethasone 2 mg tablet0.68USD tablet
Dexamethasone 1 mg/1 ml soln0.65USD ml
Dexamethasone 4 mg tablet0.6USD tablet
Dexamethasone 1 mg tablet0.49USD tablet
Pms-Dexamethasone 0.75 mg Tablet0.47USD tablet
Pms-Dexamethasone 2 mg Tablet0.43USD tablet
Dexamethasone 0.5 mg/5ml Elixir0.4USD ml
Dexamethasone 0.75 mg tablet0.38USD tablet
Dexamethasone 1.5 mg tablet0.35USD tablet
Dexamethasone 0.5 mg tablet0.31USD tablet
Apo-Dexamethasone 0.5 mg Tablet0.21USD tablet
Pms-Dexamethasone 0.5 mg Tablet0.2USD tablet
Ratio-Dexamethasone 0.5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8846650No2005-06-042025-06-04Us
US9149486No2002-09-132022-09-13Us
US6359016No2000-08-102020-08-10Us
US6284804No2000-08-102020-08-10Us
US6726918No2000-10-202020-10-20Us
US6899717No2003-11-012023-11-01Us
US8034366No2003-01-092023-01-09Us
US8506987No2003-01-092023-01-09Us
US9012437No2000-10-202020-10-20Us
US8043628No2000-10-202020-10-20Us
US8088407No2000-10-202020-10-20Us
US9283178No2000-10-202020-10-20Us
US9192511No2003-01-092023-01-09Us
US8063031No2000-10-202020-10-20Us
US7033605No2000-10-202020-10-20Us
US7767223No2001-11-282021-11-28Us
US8034370No2003-01-092023-01-09Us
US7795316No2008-08-032028-08-03Us
US8101582No2007-12-192027-12-19Us
US8450287No2007-12-192027-12-19Us
US9345714No2002-09-132022-09-13Us
US9402805No2002-09-132022-09-13Us
US9592242No2000-10-202020-10-20Us
US9775849No2000-10-202020-10-20Us
US6960346No2003-07-032023-07-03Us
US7560120No2002-09-052022-09-05Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)170-229Fried, J.; US. Patent 2,852.51 1; September 16, 1958; assigned to Olin Mathieson Chemical Corporation. Muller, G., Bardoneschi, R. and Jolly, J.; U.S. Patent 3,007,923; November 7, 1961; assigned to Les Laboratories Francais de Chimiotherapie, France.
water solubility89 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.83HANSCH,C ET AL. (1995)
logS-3.64ADME Research, USCD
Caco2 permeability-4.75ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.83 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01ot-0904000000-dbbc479b104fbe981ce7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-c84b561c97b1277fed56
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-b498846e21073040b905
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0900000000-b04e175289861dc518f1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0900000000-b04e175289861dc518f1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-01ot-0904000000-dbbc479b104fbe981ce7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-c84b561c97b1277fed56
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0903000000-b498846e21073040b905
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006w-0719000000-d4feef3f83ca022aa94d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0913000000-3c8e5afb526637f1e822
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0910000000-57f268bed9b190ee6066
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-cfdda545a27ec16c8b76
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-c70817ad99741f01b675
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0009000000-ecbabc9fe90444b14afe
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fr-0019000000-4161bdd8f3deed25b9bc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002r-0594000000-bf4495b7906d53ad019d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ds-0980000000-c4e88ec70fa28252f6f7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fs-0930000000-8022e38d862953c2551b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fs-1920000000-6f1a7ac153a363c2aa73
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00tf-1910000000-e34981c957b125a39447
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fr-0019000000-285cd2de8c812f1c5e55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002r-0593000000-bd52212afb3af2380901
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ds-0980000000-ff265e4738c79efad9e3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0940000000-818b114d12290dc23743
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fs-1930000000-9e4283fb9c2780729f55
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05dm-1920000000-0f41e220b5d3d1abe699
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0009000000-cf986616b1138d5569c7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dl-0009000000-431895662c53cadb563c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4r-0498000000-233b2490f89112ad539e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000j-0791000000-c83a21019f43596e6804
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dj-0970000000-36eebd63d78f040ae67f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dj-0940000000-730013951a30cf080ad4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0696000000-1df7921eb1369fef69c4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3960000000-e9ee044790c0655981b1

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:41879) / Pregnane and derivatives [Fig] (C15643)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Warne JP, John CD, Christian HC, Morris JF, Flower RJ, Sugden D, Solito E, Gillies GE, Buckingham JC: Gene deletion reveals roles for annexin A1 in the regulation of lipolysis and IL-6 release in epididymal adipose tissue. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1264-73. Epub 2006 Jul 11. [PubMed:16835395]
  2. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  3. Funato H, Kobayashi A, Watanabe Y: Differential effects of antidepressants on dexamethasone-induced nuclear translocation and expression of glucocorticoid receptor. Brain Res. 2006 Oct 30;1117(1):125-34. Epub 2006 Sep 7. [PubMed:16956592]
  4. Vaitkuviene A, Ulinskaite A, Meskys R, Duburs G, Klusa V, Liutkevicius E: Study of the interaction of 1,4-dihydropyridine derivatives with glucocorticoid hormone receptors from the rat liver. Pharmacol Rep. 2006 Jul-Aug;58(4):551-8. [PubMed:16963802]
  5. Wang D, Zhang H, Lang F, Yun CC: Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor. Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404. Epub 2006 Sep 13. [PubMed:16971495]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Stimulator
General Function
Transcription factor binding
Specific Function
Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional act...
Gene Name
NR0B1
Uniprot ID
P51843
Uniprot Name
Nuclear receptor subfamily 0 group B member 1
Molecular Weight
51717.185 Da
References
  1. Gummow BM, Scheys JO, Cancelli VR, Hammer GD: Reciprocal regulation of a glucocorticoid receptor-steroidogenic factor-1 transcription complex on the Dax-1 promoter by glucocorticoids and adrenocorticotropic hormone in the adrenal cortex. Mol Endocrinol. 2006 Nov;20(11):2711-23. Epub 2006 Jul 20. [PubMed:16857744]
  2. Yu CC, Li PH: In vivo inhibition of steroidogenic acute regulatory protein expression by dexamethasone parallels induction of the negative transcription factor DAX-1. Endocrine. 2006 Dec;30(3):313-23. [PubMed:17526944]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Structural molecule activity
Specific Function
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
Gene Name
ANXA1
Uniprot ID
P04083
Uniprot Name
Annexin A1
Molecular Weight
38713.855 Da
References
  1. Morand EF, Hall P, Hutchinson P, Yang YH: Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006;2006(2):73835. [PubMed:16883066]
  2. John CD, Theogaraj E, Christian HC, Morris JF, Smith SF, Buckingham JC: Time-specific effects of perinatal glucocorticoid treatment on anterior pituitary morphology, annexin 1 expression and adrenocorticotrophic hormone secretion in the adult female rat. J Neuroendocrinol. 2006 Dec;18(12):949-59. [PubMed:17076770]
  3. Davies E, Omer S, Buckingham JC, Morris JF, Christian HC: Expression and externalization of annexin 1 in the adrenal gland: structure and function of the adrenal gland in annexin 1-null mutant mice. Endocrinology. 2007 Mar;148(3):1030-8. Epub 2006 Dec 7. [PubMed:17158208]
  4. Wang C, Wang J, Guo HF, Liu RY: Involvement of annexin I in the dexamethasone-mediated upregulation of A549 cells phagocytosis of apoptotic eosinophils. Immunol Lett. 2007 Aug 15;111(2):103-10. Epub 2007 Jul 2. [PubMed:17644190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
Gene Name
NOS2
Uniprot ID
P35228
Uniprot Name
Nitric oxide synthase, inducible
Molecular Weight
131116.3 Da
References
  1. Soderberg M, Raffalli-Mathieu F, Lang MA: Regulation of the murine inducible nitric oxide synthase gene by dexamethasone involves a heterogeneous nuclear ribonucleoprotein I (hnRNPI) dependent pathway. Mol Immunol. 2007 May;44(12):3204-10. Epub 2007 Mar 26. [PubMed:17379310]
  2. Huang H, Lavoie-Lamoureux A, Moran K, Lavoie JP: IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1147-54. [PubMed:17494951]
  3. Nandi J, Saud B, Zinkievich JM, Palma DT, Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 2008 Jan;53(1):123-32. Epub 2007 May 15. [PubMed:17503181]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28. [PubMed:16054614]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name
CYP11A1
Uniprot ID
P05108
Uniprot Name
Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V: Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001 Oct 5;167(1):37-46. [PubMed:11557128]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  3. Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32. [PubMed:8845310]
  4. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  7. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]
  8. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705. [PubMed:7560060]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R: Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett. 1999 Jan 15;442(2-3):208-14. [PubMed:9929003]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6. [PubMed:9539145]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Elahian F, Kalalinia F, Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 2010 Apr;33(2):113-9. doi: 10.3109/01480540903390000. [PubMed:20307139]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:50